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1 Introduction 
1.1 Tuberculosis 
Tuberculosis (TB) is one of the oldest diseases known to humanity [1]. While for 
thousands of years its etiology had been mysterious, it is today known to be 
caused by bacteria. TB is described as a disease of poverty and ranks among 
the five most common causes of death due to infectious diseases worldwide [2]. 
In our globalized world new challenges are arising in the fight against TB, such 
as its epidemiologic promotion through the human immunodeficiency virus (HIV) 
pandemic and the emergence of drug resistances. However, global collaboration 
efforts have brought up new tools towards disease control and the human 
potential to overcome the threat has reached an unprecedented high. 
1.1.1 Epidemiology 
The illustration of the current epidemiological situation of TB as described in the 
following section refers to the World Health Organization (WHO) global 
tuberculosis report 2014 [3] unless otherwise noted. 
In 2013, 20 years after TB has been declared a public health emergency by the 
WHO, global strategies and joint efforts to fight the disease are showing effect: 
global incidence is falling and prevention of deaths due to TB is on track to reach 
the targets set by the global community for 2015. However, some regions are 
dropping behind in effective disease control. The central African country Gabon 
is particularly affected, requiring special attention now in order to achieve global 
TB control. 
1.1.1.1 TB incidence 
In 2013 there has been a total number of 9.0 million new TB cases worldwide, 
equivalent to 126 cases per 100,000 population. After an incidence peak in 2003 
with an estimated 9.3 million new cases, incidence has been slowly declining by 
about 2% per year. The Millennium Development Goal of halting the rise in 
incidence before 2015 (section 1.2.2.) has been reached since around a decade. 
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In absolute numbers the Asian Region* harbors the highest incidence (56% of 
new cases in 2013) with India and China in lead. The numbers of incident TB 
cases relative to population size however are highest in southern Africa with 
Swaziland, Lesotho and South Africa being the leading countries with up to 1000 
new cases per 100,000 population. TB hot spots outside Africa include Myanmar, 
Cambodia, the Philippines and Pakistan.  
With an incidence rate of estimated 423 per 100.000 population in 2013, Gabon 
ranks among the top ten countries worldwide. 
1.1.1.2 TB mortality 
In 2013, 1.5 million people have died from TB with an estimated  360,000 being 
co-infected with the human immunodeficiency virus (HIV). Mortality rates have 
been falling by around 45% since 1990, but forecasts suggest that an accelerated 
decline would have been necessary to reach the target of the Stop TB partnership 
to reduce them by 50% until 2015. Approximately 78% of all TB deaths occurred 
in the African and South East Asian Region*. Mortality is declining in all six 
regions and the regions of the Americas and the West pacific region have already 
reached the target. 
In Gabon, 910 and 180 deaths from TB were reported in 2013 in HIV uninfected 
and infected patients, respectively, showing the disease to be a considerable 
cause of death in the country [4]. 
1.1.1.3 TB prevalence 
Eleven million people have suffered from TB in 2013, equivalent to 159 cases per 
100,000 people. Although prevalence has fallen since 1990 by 41% forecasts 
suggest that the Stop TB Partnership target of halving TB prevalence by 2015 
has not been reached. Prevalence is falling in all six WHO regions. While the 
target has been reached in the region of the Americas and West Pacific Region, 
                                            
* Regions defined by WHO:  
http://www.who.int/about/regions/en/ [last accessed: August 18, 2015] 
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is seems unlikely to be reached in the African and Eastern Mediterranean 
Regions. 
With 578 per 100.000 population having suffered from TB in 2013, Gabon is 
among the high-prevalence countries [4]. 
1.1.1.4 HIV/TB co-infection 
Since the 1980s, the HIV pandemic has become a major public health threat 
globally and in many African countries. The HIV pandemic was a driving source 
for the re-emergence of TB. In 2013, 1.1 million (13%) of new TB patients were 
co-infected with HIV, 78% of which were from the African Region. In the African 
Region, 34% of new TB cases were HIV co-infected. 
In Gabon, while an HIV/TB co-Infection rate of 11% has been reported to the 
WHO in 2013 [4], some studies give evidence of much higher rates of up to 46% 
in the last years [5-7]. 
Linking-up of efforts to fight TB and HIV in an integrated approach is now 
accepted as mandatory to overcome the co-pandemic [8, 9]. Remarkable efforts 
have been made following the WHO recommendations on interventions needed 
to prevent, diagnose and treat TB in people living with HIV [10]: in 2013, 48% of 
globally notified TB cases have been tested for HIV, showing a more than 15-fold 
increase from 2004. 76% have been tested in the African Region, and 100% in 
Gabon according to WHO data [4]. However, the worldwide target of antiretroviral 
therapy (ART) coverage for all TB patients living with HIV is still far: 70% of global 
HIV co-infected TB patients have been on ART in 2013 and 69% in the African 
region. Equally, further effort is required in providing isoniazid preventive therapy 
(IPT) to people living with HIV who do not have active TB: in 2012, globally 31% 
received IPT, which is below the target of the 50% in eligible patients [11]. For 
Gabon, data on ARV and IPT coverage is urgently needed. 
1.1.1.5 Drug resistant tuberculosis 
The emergence of drug resistant M. tuberculosis strains (DR-TB) is one of the 
major challenges in the global fight against TB. Multi-drug resistant TB (MDR-TB) 
is defined as resistance to at least isoniazid (INH) and rifampicin (RIF), the two 
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most efficient drugs. Extensively-drug resistant TB (XDR-TB) is defined as 
resistance to INH and RIF as well as any fluoroquinolone and any of the second-
line injectable drugs [12] (section 1.1.6). 
In 2013, 3.5% of newly diagnosed TB cases and 20.5% of retreatment were 
MDR-TB on a global scale. While India and China harbor the highest total burden 
of MDR-TB, the highest proportions are found in Eastern Europe and central Asia. 
In Belarus, 35% of new cases and 55% of retreatment cases were due to MDR-
TB. XDR-TB was found in 9.0% of global MDR-TB cases and was reported in 
100 countries by the end of 2013. The proliferation of Xpert MTB/RIF usage 
(section 1.1.5.6) helped to delineate extends of MDR-TB and detection rates have 
increased by 42% from 2011 to 2012. While on a global scale second-line 
treatment was started in 71% of MDR-TB patients notified, only 44% of MDR-TB 
patients in the African Region received appropriate treatment and waiting lists for 
second-line treatments persist or grow in several countries. The absolute number 
of newly started second-line treatments increased by more than two times from 
2009 to 2013 [11]. 
For Gabon only anecdotal data report on the existence of MDR-TB [13] and valid 
data on the local MDR-TB burden and available treatment options is urgently 
needed. In 2013, 2.6% of new TB cases and 13% of retreatment cases were 
estimated by WHO to be MDR-TB [4]. However, no systematic data is available 
on drug resistances. 
1.1.1.6 TB in children 
In 2013, the WHO estimated 550,000 children to have acquired TB, which is 6% 
of total new TB cases. Eighty thousand HIV negative children infected with TB 
died in 2013 (7% of total HIV negative TB deaths). However, the value of 
available data is limited due to both underreporting of TB in children and frequent 
misdiagnosis [14]. 
In Gabon, 4% of new TB cases were notified to be children younger than 15 years 
old [4]. 
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1.1.2 Causative organisms 
The following description of the microbiological characteristics of mycobacteria 
refers to the “Comprehensive Clinical Reference” by Schaaf and Zumla [15] 
unless otherwise noted. 
Tuberculosis disease in humans and other mammals are caused by 
mycobacteria of the mycobacterium tuberculosis (M.tb.) complex. Mycobacteria 
are aerobic, non-motile, non-spore forming, non-encapsulated, acid-fasts rods. 
They are classified as acid-fast due to the fact that the lipid-rich cell wall is 
relatively impermeable to most dyes, requiring a special stain for microscopy 
(section 1.1.5.3). 
In principal, mycobacteria can be divided into two slow growers and rapid 
growers. Both have simple nutritional requirements and are able to grow and 
survive in difficult conditions. Slow growers take up to 24 hours to divide, which 
is extremely slow compared to other bacteria. While they are divided ecologically 
into obligate pathogens and so-called environmental mycobacteria, the most 
important differentiation from a medical point of view is that into M.tb. complex 
and Non-tuberculous mycobacteria (NTM). 
Mycobacteria of the M.tb. complex are obligate intracellular pathogens, which 
persist in macrophages and thereby avoid human immune responses (section 
1.1.3.2). Species grouped in the M.tb. complex are M. tuberculosis, M. africanum, 
M. bovis, M. microti and M. canetti [16]. 
M. tuberculosis is the major cause for TB in humans and also the first 
mycobacterium discovered and identified by Robert Koch in 1882 [16]. M. 
africanum is the name of a heterogeneous group of strains isolated from patients 
in equatorial Africa. M. bovis is mainly causing TB in cattle, but has the ability to 
cross the species barrier and caused around 6% of all human TB deaths in 
Europe before the introduction of milk pasteurization [16]. 
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1.1.3 Pathophysiology 
The illustration of the pathophysiological specifics of TB as described in the 
following section refers to “Robbins Basic Pathology” 8th edition [17] unless 
otherwise noted. 
1.1.3.1 Transmission 
Transmission occurs predominantly by inhalation of aerosols arising from 
expectoration of infected persons. More uncommon ways of transmission include 
digestion of unpasteurized milk or direct inoculation of mycobacteria. 
The pathogenesis and host response differ crucially between immunocompetent 
and immunocompromised individuals as well as between those having and 
having not been previously sensitized to TB. 
1.1.3.2 Latent tuberculosis infection 
Of previously unexposed individuals being in contact with M.tb., only a small 
fraction develops active disease. Over 90% of those infected are able to clear the 
infection or contain the pathogens in a latent stage, which is called latent 
tuberculosis infection (LTBI). Individuals in this stage are asymptomatic and not 
contagious. Worldwide, the number of people with LTBI is estimated to be two 
billion [16, 18]. 
In immunocompetent individuals, the infection initiates cell-mediated immunity, 
providing resistance to the organism and tissue hypersensitivity. The latter results 
in formation of caseating granulomas and cavitation. In most cases, the host is 
able to contain the primary infection focus through granuloma formation and the 
disease fades into a latent stage. 
More specifically, mycobacteria gain entry into macrophage endosomes, but are 
able to inhibit microbicidal responses by endosomal manipulation, which includes 
change of endosomal pH and arrest of endosomal maturation.  During this phase 
mycobacteria can proliferate freely in alveolar macrophages. After approximately 
three weeks, when processed mycobacterial antigens reach the draining lymph 
nodes, cell mediated immunity develops: antigens are presented by dendritic 
cells to CD4+ T cells, which thus differentiate into TH1 cells. Through secretion of 
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interferon γ, they activate macrophages which, in turn, cause a variety of down-
stream effects, one being the recruitment of monocytes and their differentiation 
into epitheloid histiocytes, which characterize granuloma formation. 
1.1.3.3 Progressive primary tuberculosis 
In immunocompromised persons, the host immune system cannot set up the 
CD4+ cell-mediated response required to contain the primary focus, allowing the 
pathogens to spread without granuloma formation and thus leading to 
progressive primary tuberculosis. This often includes atypical forms of TB 
(section 1.1.4). The overall risk of developing progressive disease is only around 
5%, but can increase dramatically through a number of risk factors, such as 
coinfection with HIV or malnutrition and is also higher in children [16, 18, 19]. 
1.1.3.4 Secondary or postprimary TB 
Postprimary TB is the disease that develops in previously exposed individuals. It 
may either be caused by reactivation of latent TB (endogenous reactivation, more 
likely in low-prevalence areas) or by reinfection with another pathogen 
(exogenous reinfection, more likely in high-prevalence areas). The lifetime risk in 
infected persons is only about 10% and the triggers for reactivation in otherwise 
healthy individuals are not yet completely understood.  However, reactivation 
arises particularly when host immunity is weakened, e.g. due to HIV-Infection or 
malnutrition [16, 18]. 
The classical localization of lesions in postprimary TB is at the apex of the upper 
lobes of the lungs. Due to a prompt response of the host immunity, the local lymph 
nodes are less prominently involved than in primary TB. Instead the host 
response leads to cavitation and thus to dissemination along the airways and 
increased infectivity of the patient. 
In persons with advanced immunosuppression such as AIDS, the clinical picture 
resembles that of progressive primary TB. This atypical presentation of TB 
includes lower and middle lobe lesion, hilar adenopathy and extrapulmonary 
forms such as lymph node TB, pleural effusions, tuberculous meningitis and 
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miliary TB. Due to diminished destruction of bronchial walls, bacillary loads in the 
sputum are often lower than in immunocompetent individuals. 
1.1.4 Clinical course 
The classical symptoms of pulmonary TB (PTB) consist of chronic cough, weight 
loss, fever, night sweats and hemoptysis [20]. In early stages of the disease 
patients can be asymptomatic or show only mild symptoms [21]. In most cases 
cough is worsening and sputum production increasing with progressive 
pulmonary involvement. Sputum often is initially mucoid, later purulent and blood 
stained. Fever is usually of low grade and remittent [17]. 
In HIV-infected patients clinical manifestation of TB differs in correlation with the 
degree of immunosuppression. Extrapulmonary TB (EPTB) manifestations are 
more frequently seen and the classical symptoms such as purulent cough are 
often missing [22, 23], making the diagnosis more difficult. In cases of EPTB, 
symptoms depend on the organ or body site involved. Possible complains include 
pleuritic pain, lymph node swelling, neurologic deficits, infertility and others [17]. 
1.1.5 Diagnostics 
1.1.5.1 Chest x-ray 
In the vast majority of TB cases, chest x-ray films show abnormalities. The 
hallmark of primary TB is hilar or mediastinal lymphadenopathy, which is most 
common in children and decreases with age. Parenchymal involvement shows 
an opposite trend, being more common in adults [20]. 
Characteristics of postprimary TB are opacities in the apical and posterior 
segments of the upper lobes, while hilar or mediastinal lymphadenopathy is rare. 
Cavities are visible in 40-45% of cases and often show air-fluid levels. Other 
radiographic signs include pleural effusions, atelectasis and mediastinal shift [20].  
Miliary TB appears in the chest x-ray as innumerable nodules scattered 
throughout both lungs and is mostly associated with lymphadenopathy [20]. 
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1.1.5.2 Tuberculin skin testing and Interferon-Gamma-release-assay  
In 1980 Robert Koch discovered the immune response to a purified protein 
derivate (PPD) obtained from TB culture filtrates called tuberculin. Later, 
diagnostic test were developed using this tuberculin reaction by the physicians 
Felix Mendel and Charles Mantoux. Thus the test is also called Mendel-Mantoux 
Test [24]. 
Tuberculin causes a delayed type hypersensitivity reaction when injected in the 
skin of a person currently or previously infected with M.tb. The host response is 
detectable starting from 2-12 weeks after infection. The reaction usually begins 
5-6 hours after injection and reaches its maximum after 48-72 hours [25]. 
The Tuberculin Skin Test (TST) cannot differentiate between active and latent TB 
infections. Its value is limited by its sensitivity and specifity: false-negative 
reactions can be caused through cutaneous anergy due to immunosuppression 
as seen in HIV or malnutrition, but also in overwhelming TB disease. False-
positive reactions occur after contact with NTM and in persons who have been 
vaccinated with BCG [25]. 
Against the background of these limitations, another method was developed: the 
interferon-gamma-release-assay (IGRA). This blood test measures the immune 
response to M.tb. antigens. Secretion of IFNγ by specific effector memory t-cells 
of the host is stimulated in vitro through exposure with M.tb. antigens. The level 
of secreted IFNγ varies between exposed and unexposed individuals [26]. 
IGRAs have shown to be less prone to false-positive results caused by NTM or 
BCG-vaccine. However, they are not more sensitive than TST and they are not 
useful in the differentiation of active and latent TB, neither can they rule out a 
LTBI [27]. 
According to WHO, IGRAs are not preferable to TSTs in low- and middle-income 
countries with high TB and/or HIV burdens [28]. 
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1.1.5.3 Microscopy 
The diagnosis of mycobacteria through microscopy is the oldest available 
diagnostic method, and still the most commonly used method in many low-and 
middle income countries. Smear microscopy is done mainly from sputum 
samples, but can also be done from gastric aspirates or extrapulmonary samples 
such as lymph node aspirate or pleural fluid. Since mycobacteria are acid-fast 
bacilli they need a special preparation and staining. 
A) Ziehl-Neelsen (ZN) stain 
This is the “conventional” method with a long history of clinical use. The 
preparation for this stain includes coloration with carbol fuchsin, decolorization 
with acid alcohol and a counterstain with methylene blue. Reading is done with 
an ordinary microscope. While this method is quite specific for mycobacteria, 
sensitivity only reaches 54 – 64% [29], making different or complementary 
diagnostic steps necessary. 
B) Fluorochrome staining 
The preparation for this stain is done with the acid-fast dye auramine, 
decolorization with acid alcohol and counterstain with potassium permanganate 
solution. Reading requires a ultraviolet (UV) microscope with an intense light 
source. Fluorescence microscopy (FM) allows faster screening methods, is more 
sensitive and equally specific compared to the ZN method [29, 30]. 
While traditional fluorescence microscopes are expensive, equally sensitive and 
much cheaper fluorescence microscopes with light-emitting diodes (LEDs) can 
be used [31]. 
1.1.5.4 Culture and drug susceptibility testing 
While culture is the gold-standard for the detection of M.tb., it is difficult due to 
the slow growth of mycobacteria and the required infrastructure often not 
available in low-income countries. 
A) Solid medium 
The first method invented to culture mycobacteria was an egg-based solid agar 
called Löwenstein-Jensen (LJ) Agar. Limitations to this method are the low 
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sensitivity (62%) and the long detection time of around one month in average 
[32]. 
In 1958, Middlebrook and Cohn described the earlier detection of mycobacteria 
under growth stimulation with carbon dioxide . However, average detection times 
with this method are still three to four weeks [33]. 
B) Radiometric method 
A method using 14C-labeled palmitic acid for the radiometric detection of 
mycobacteria growth was introduced in the 1980s, called the BACTEC 460 TB 
System. It showed increased sensitivity and significant reduction in detection time 
compared with the conventional solid method, with an average detection time of 
around two weeks [32]. 
C) Mycobacteria Growth Indicator Tube (MGIT) 
Due to the problems regarding the use of radioactive substrate, development of 
a non-radiometric technique was promoted, resulting in the development of the 
Mycobacteria Growth Indicator Tube.  
The MGIT system is based on growth of mycobacteria in a liquid medium. The 
tube contains a fluorochrome which is initially inhibited by free oxygen but starts 
to fluoresce when oxygen is used by growing mycobacteria. Reading is done 
under UV light manually or automatically [30]. Showing similar sensitivity but 
clearly shorter detection time than conventional methods, and not having the 
disadvantages of radiometric methods, MGIT is the gold standard for detection 
of mycobacteria today [16, 34]. 
D) Drug susceptibility testing (DST) 
Drug susceptibility testing can be done with all culturing methods mentioned 
above. In principal growth in two sub-cultures is compared, one with an added 
test drug (section 1.1.6). Both automated and manual MGIT have shown to be as 
accurate and rapid as conventional methods [35] and have therefore been 
recommended by the WHO to be used in low-and middle-income countries [36]. 
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For resource-constrained settings, inexpensive alternatives such as 
microscopically observed drug susceptibility or nitrate reductase assay have 
been recommended as an interim solution [31]. 
1.1.5.5 Line-probe-assays 
Line probe assays allow rapid molecular testing for resistances in M.tb. They can 
be performed with culture isolates or directly to smear positive sputum 
specimens. The GenoType MTBDR assay (Hain LifeScience GmbH, Nehren, 
Germany) allows detection of RIF and INH resistance genes and therefore rapid 
diagnosis of MDR-TB [37].  
The GenoType MTBDRsl allows resistance testing on important second-line TB 
drugs, therefore being an effective measure to diagnose XDR-TB [38]. 
1.1.5.6 Automated nucleic acid amplification tests 
One of the newest and most promising developments in TB diagnostic is the 
Xpert MTB/RIF. It uses series of molecular line probe assays and real-time 
polymerase chain reaction (PCR) to detect M.tb. and RIF resistance genes. 
Sensitivity in smear positive and smear negative pulmonary TB reached 98% and 
73%, respectively, and specifity was 99%. Moreover, TB diagnosis and 
resistance testing can be achieved within hours, giving this fully automated and 
commercially available diagnostic tool the potential to become a major 
breakthrough in TB diagnostics [16]. 
1.1.5.7 Serologic and other assays 
The use of serologic tests in the diagnosis of TB has been discouraged by the 
WHO [39] due to a lack of sensitivity [40]. In contrast, a urine test for the 
mycobacterial antigen lipoarabinomannan (LAM-test) has been shown to have 
increased sensitivity in HIV patients with advanced immunodeficiency [41]. Being 
still in development, it might be an attractive tool combined with microscopy in 
settings with high HIV burden. 
1.1.5.8 TB diagnostic capacity available in Gabon 
By the time of study, TB was diagnosed on clinical ground supported by 
conventional smear microscopy as only available microbiological tool in Gabon; 
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culture and DST were not available outside study settings. Equally, any rapid 
diagnostic tool, such as the Xpert MTB/RIF was not available. Therefore, data on 
the epidemiology of TB in Gabon, especially data on drug resistance, can only be 
considered as estimates. 
1.1.6 Antituberculous treatment 
Treatment recommendations have been last revised by the WHO in 2010 [42] 
and the following section refers to these recommendations unless otherwise 
noted. Treatment for TB is based on a combined chemotherapy with several 
antibiotics. Current treatment regimens last over at least 6 months, but can be 
much longer depending on drug susceptibility. In general, treatment can be 
divided in a shorter intensive phase and a longer continuation or consolidation 
phase. 
1.1.6.1 First-line drug regimens 
In TB patients with drug susceptible TB, treatment should be done with first-line 
drugs, which have best ratios of efficacy and adverse effects. First-line oral 
agents are INH, RIF, ethambutol (EMB), pyrazinamide (PZA) and streptomycin 
(STR). The most effective drugs, INH and RIF are indicated throughout the whole 
course of the treatment, while other drugs may be stopped in the continuation 
phase, depending on the treatment regimen. Drug intake should be daily and 
ideally under direct observation (section 1.2.1). 
If possible, every patient should get DST at the beginning of his treatment in order 
to have the ability to adapt treatment to the resistance profile of the M.tb. strain. 
During treatment, regular supervision is crucial in order to detect treatment failure 
and adverse effects. The effect of treatment should be monitored bacteriologically 
in terms of sputum conversion. 
Retreatment regimens can differ from those for new patients, since there is 
increased risk of drug resistances. They should be defined by national TB 
programs taking into account the local resistance data. 
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1.1.6.2 Second-line drug regimens 
In case of drug resistances, especially MDR-TB, a second-line drug regimen 
should be used. Second-line drugs are generally less effective and have more 
adverse effects. They are parenteral, such as kanamycin, amikacin (AM) and 
capreomycin (CM) or oral, such as ofloxacin (OFX), ethionamide (ETO), 
cycloserine (CS) and para-aminosalicylic acid (PAS). Second-line drug regimens 
should contain at least four effective drugs and be directly observed during the 
whole course of the treatment. Monitoring of treatment effects requires monthly 
smears and cultures until culture conversion and then at least another 18 months 
of treatment [43]. 
1.2 Global strategies to fight tuberculosis  
During the 44th World Health Assembly in 1991, global strategies to fight TB were 
recognized to be insufficient, regarding the increasing incidence in developing as 
well as industrialized countries. The need for worldwide political commitment was 
stressed, and initially two targets were set: Achieving 1) a worldwide case 
detection rate of 70% and 2) a worldwide cure rate of 85% until the year 2000 
[44]. Later these targets were postponed to 2005. 
1.2.1 DOTS 
In 1993 the WHO declared TB to be a public health emergency. Subsequently 
increased efforts to improve TB care were made at national and international 
levels, resulting in the development of the DOTS strategy. DOTS means “Directly 
Observed Therapy, short course” and is a framework for effective TB control 
developed by the WHO in 1994 [45]. Its five basic components include: 
 Political commitment with increased and sustained financing 
 Case detection through quality-assured bacteriology 
 Standardized treatment with supervision and patient support 
 An effective drug supply and management system 
 A standardized monitoring and evaluation system and impact 
measurement  
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1.2.2 Millennium development goals and the STOP TB Partnership 
During the millennium assembly of the United Nations in 2000, eight goals were 
set for the year 2015, the Millennium development goals (MDG). Goal 6c 
specifically addresses TB: “halt and begin to reverse the incidence of tuberculosis 
by 2015” [46]. 
Although many countries have adopted the DOTS strategy and there was 
considerable progress towards the target, additional efforts seemed to be 
necessary for global TB control. Following two political commitments to stop TB 
in Amsterdam [47] and Washington [48], the global Stop TB partnership was 
founded in 2001.The Stop TB Partnership is an international organization closely 
linked to the WHO. Its six components are: 
 Pursue high-quality DOTS expansion and enhancement. 
 Address TB and HIV, multidrug resistant TB, and the needs of poor and 
vulnerable populations. 
 Help improve health policies, human resource development, financing, 
supplies, service delivery, and information. 
 Engage all care providers. 
 Empower people with TB and communities through partnership. 
 Enable and promote research 
Its major first action was the publication of the “First Global Plan to Stop TB 2000-
2005” and the setting of additional targets linked to the MDG: 1) By 2015, reduce 
the prevalence of TB and deaths due to TB by 50% compared with the baseline 
of 1990 and 2) By 2050, eliminate TB as a public health problem as defined by 
achieving a worldwide incidence of TB of less than one case per million 
population per year [46, 49]. 
Each in 2006 and 2010, the Global Plan to Stop TB was reevaluated and updates 
were published with scenarios how to reach the targets in regions with high 
burden of TB and more specific guidance on how to reach the targets [50, 51]. 
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A post-2015 global TB strategy (the End TB strategy) has been developed in 
2013 and approved by all Member States at the May 2014 World Health 
Assembly [52]. 
1.3 TB Treatment outcomes 
Over the last two decades, TB treatment success has remarkably improved on a 
global level. From a success rate of 57% in 1995 in new smear positive TB cases, 
it has risen to 86% in 2012, meeting the target of 85% set in 1991 [3]. This 
progress can be attributed to global efforts and strategies, such as the increasing 
implementation and acceptance of DOTS [53] (section 1.2.1), strengthening of 
national TB programs and increased financial aid. New molecular diagnostics and 
the development of new drugs and vaccines offer promise for further 
improvement of TB control [16].  
In principal, classification of treatment outcomes is done differently between 
patients with drug-susceptible TB and those with MDR-TB receiving second-line 
treatment. Different outcomes as defined by the WHO are successful treatment, 
treatment failure, loss to follow up, and death. Treatment success can be 
assessed clinically (treatment completed) or, better, microbiologically by sputum 
conversion (cured) [42]. 
1.3.1 Treatment outcomes of drug-susceptible TB 
In 2012, 86% of worldwide new TB cases have been treated successfully. The 
American and European regions are behind, having a 76% and 75% treatment 
success rate in 2012, respectively [3]. 
According to data reported to the WHO, in the African region treatment success 
was 79% in 2011, 6.2% of TB patients died, 0.9% of treatments failed and 5.6% 
of patients defaulted [54]. For Central Africa, data of high quality and visibility is 
scarce. Published epidemiological studies from Gabon are mainly retrospective, 
available exclusively in French, and refer to particular subgroups. However, the 
little data available suggests that in the time period between 2004 and 2012 
treatment success in Gabon has been alarmingly low (39-48%) [7, 54] and 
defaulting rates exceptionally high (28-61%) [5, 7, 54]. 
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1.3.2 Treatment outcomes of drug resistant TB 
In 2011 the global treatment success for MDR-TB rate was 48%, while in 25% of 
treatments patients were lost to follow up or no outcome was reported. Treatment 
success was best in the Eastern Mediterranean (64%) and lowest in the African 
and European Region with less than half of the patients treated successfully. The 
target of a 75% treatment success rate set by the Stop TB Partnership was 
reached only by 29 out of 126 countries [3]. 
In 2009, a meta-analysis of treatment outcomes of MDR-TB patients under strict 
DOTS conditions found a pooled success proportion of 69% [55]. A study on 
XDR-TB in South Africa showed culture conversion in only 20% and deaths in 
42% [56]. 
A recent case series on drug resistant TB cases in Gabon reported that only 3 
out of 16 patients (18%) were cured and 5 (31%) died [13]. 
1.4 Barriers towards successful TB treatment 
On the way to global TB control, treatment outcome is crucial: while successful 
treatment does not only reduce morbidity and mortality but prevents further 
transmission of the disease, adverse treatment outcome increases the local 
disease burden, therefore also placing a higher financial strain on the country. 
Moreover, high defaulting and treatment failure rates bare the risk to fuel the 
emergence as well as the spread of drug resistances and therefore endanger 
disease control also on a global level. 
Worldwide, the greatest barriers towards successful treatment are the 
emergence and spread of drug resistances and the insufficient management of 
HIV co-infections [11]. Furthermore, the global economic crisis endangers 
successful treatment by posing economic barriers in low-income countries, 
causing unbearable treatment costs for patients and insufficient drug supply 
through the governments [18, 57, 58]. Besides, other problems identified as 
cause of adverse treatment outcome remain unsolved [59]. These include 
geographical barriers [60], gender differences [61, 62], stigmatization and 
malnutrition [63, 64]. 
22 
 
 
 
For Gabon, reasons for adverse TB treatment outcome are insufficiently 
understood. Almost no data are available about the extent and outcome of DR-
TB. The few data on HIV co-infection rates in TB patients suggests a major public 
health challenge, but more data are required to evaluate integration of TB and 
HIV services and quantify treatment outcome. Evidence of dramatic defaulting 
rates and alarmingly low treatment success rates suggest failure of the national 
TB program and a lag in TB control compared to the African average and the rest 
of the world. Here too further investigation is necessary. 
1.5 Study rationale 
The rationale of the Panepi study (section 2.1) and this thesis is to prospectively 
investigate local TB epidemiology, quantify TB treatment outcome in a semi-rural 
area in Gabon and to identify determinants of successful and unsuccessful TB 
treatment.  
Special emphasis is set on the extent and outcome of drug resistant TB, the 
outcome of TB/HIV co-infection and the investigation of high defaulting rates in 
Gabon. Furthermore, the correlation of potential other risk factors and treatment 
outcome in Gabon is investigated.  
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2 Methods 
2.1 Study design and objectives 
The Panacea Epidemiology (Panepi) study was a prospective observational 
epidemiologic cohort study assessing patients treated for TB disease. The full 
title was “Epidemiology of Tuberculosis in Lambaréné”.  
The overall study objective was to assess the local TB burden, including 
demographic, clinical, microbiological, and treatment outcome aspects of TB. The 
study was conducted in close collaboration with Gabon’s national TB program 
“Programme national de lutte contre la tuberculose” (PNLTB). 
Specific objectives of the study were the evaluation of the: 
 Rate of TB/HIV co-infection 
 Rate and patterns of DR-TB, especially MDR-TB 
 Treatment outcomes 
 Risk factors for unfavorable treatment outcome and reasons for non- 
adherence to treatment regimens 
2.2 Study setting 
2.2.1 Study period 
The study was conducted between June 2012 and July 2015. Recruitment of 
study participants took place between June 2012 and October 2013. The last 
follow up visit was done in June 2014. Microbiological analysis were completed 
in September 2014. Data analysis was completed in July 2015. 
2.2.2 Study sites 
All involved Gabonese study sites are located in Lambaréné, a 30,000 inhabitant 
town in a semi-rural area in the Moyen-Ogooué province of Gabon. 
2.2.2.1 Centre de Recherches Médicales de Lambaréné (CERMEL) : 
The CERMEL is situated next to the Albert Schweitzer Hospital. It consists of 
several laboratories, such as the TB laboratory, a clinical laboratory, a 
parasitology laboratory, a microbiology laboratory as well as an immunology 
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laboratory. At the CERMEL numerous epidemiological studies and clinical trials, 
have been conducted; a main focus has been on malaria. For some years 
CERMEL is expanding its research activities to other important diseases endemic 
in sub-Saharan Africa such as TB and nosocomial infections, as well as to 
immunological studies. 
At the time of study the TB laboratory provided the infrastructure for study 
planning, coordination and handling of samples for studies on TB and HIV. 
Besides, parts of screening, recruitment and follow up procedures were done 
here as well. Data storage, data entry and first data analyzes are also performed 
at the TB laboratory of CERMEL. Laboratory procedures performed at the TB 
laboratory of CERMEL comprised sputum microscopy (ZN and FM), sputum 
conservation and preparation of samples for shipment to Germany. At the time of 
study, no validated mycobacterial culture was available on site. Furthermore, HIV 
testing as well as hematology and biochemistry analyzes were done at the clinical 
laboratory of CERMEL.  
2.2.2.2 Hôpital Albert Schweitzer de Lambaréné (HAS): 
HAS is the biggest hospital in Lambaréné and has a total capacity of 150 beds. 
It has an internal medicine ward, a pediatric ward, a maternity ward and a surgical 
ward as well as an emergency room. The laboratory belonging to the hospital 
performs sputum microscopy (ZN stain), HIV testing, hematology and 
biochemistry analyzes. The radiology department of the hospital is able to provide 
x-ray films in digital or printed form but no radiologist is on site. Routinely, TB 
patients cared for at HAS are admitted to the internal medicine or pediatric ward 
and followed up at the outpatient department. In the context of this study, patients 
with suggestive TB were referred to the CERMEL, after having been consulted in 
an outpatient setting. 
2.2.2.3 Centre Hospitalier Regional “Georges Rawiri” de Lambaréné 
(CHRGR) 
CHRGR is the second biggest hospital in Lambaréné next to HAS. The hospital 
laboratory performs HIV testing, hematology and biochemistry analysis, but no 
sputum examination. The radiology department of the hospital is able to provide 
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x-ray films in printed form. Routinely, TB patients cared for at CHRGR are 
admitted at the internal medicine ward and followed up at the outpatient 
department. In the context of this study, sputum and other samples eligible for 
mycobacterial search were sent to the TB laboratory of CERMEL for analysis.  
2.2.2.4 Centre de Traitement Ambulatoire (CTA) 
CTA is the HIV clinic in Lambaréné. It provides outpatient HIV testing, counseling 
and treatment. Patients are not admitted, but referred to HAS or CHRGR if in-
hospital treatment is indicated. On the other hand, HIV patients from other health 
care centers, such as CHRGR are referred to CTA for HIV counseling and 
treatment. The laboratory performs HIV testing as well as hematology and 
biochemistry, but no sputum examination. A radiology department is able to 
provide x-ray films in printed form. TB patients co-infected with HIV receive 
ambulatory antituberculous treatment at CTA. In the context of this study, sputum 
and other samples eligible for mycobacterial search were sent to the TB 
laboratory of the CERMEL for analysis. 
2.2.2.5 Base d’épidémiologie (BELE) 
BELE is the TB clinic in Lambaréné and in charge of implementation of the 
national TB program PNLTB. It provides counseling and treatment for TB, but not 
sputum examination, blood analysis or x-ray. Routinely, TB patients receive 
ambulatory treatment at BELE. In the context of this study, sputum and other 
samples eligible for mycobacterial search were sent to the TB laboratory of the 
CERMEL for analysis.  
2.2.2.6 National Reference Center (NRC) for mycobacteria in 
Borstel/Germany 
The NRC for mycobacteria in Germany participates in the coordination of 
measures in the fight against and the surveillance of TB and acts as a 
supranational reference laboratory of the WHO.  
At the time of study, the NRC in Borstel performed culture and identification of 
mycobacteria, as well as DST and quality control of sputum microscopy 
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performed in Lambaréné. All sputa examined at CERMEL were conserved and 
shipped to Borstel. 
2.2.3 Study population 
The study population consisted of patients being treated for active TB in the 
various health care institutions caring for TB patients in Lambaréné. Adults as 
well as children with TB were enrolled in the study. Participants lived in urban as 
well as semi-urban and rural areas.  
2.2.4 Inclusion and exclusion Criteria 
Inclusion criteria were: 
 Initiation of curative TB treatment 
 Provision of informed consent for participation in the TB epidemiology 
study; in case of minority the participant’s legal representative had to give 
informed consent. 
There were no specific exclusion criteria. 
2.3 Study procedures 
An overview of the study flow regarding clinical and microbiologic study 
procedures is presented in Figure 1. 
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Figure 1: Study flow 
Time period: June 2012 – June 2014, TB: tuberculosis, M2: month two, M6: month six 
2.3.1 Clinical procedures 
2.3.1.1 Consenting procedure 
Patients with symptoms suggestive of TB and initiating TB workup were 
approached and invited for participation in the TB epidemiology study. The study 
was explained in detail (risks, requirements, samples to be taken and analyzed, 
etc.). A copy of the informed consent form in French was given to the patients to 
read. For illiterate patients, the investigator read the informed consent form to 
them. Any questions and/or concerns voiced by the patients were answered by 
designated study staff. If the patients were willing to participate, they were asked 
to sign the informed consent. For illiterate patients a thumb fingerprint was asked 
for instead of a signature and this was witnessed by an independent literate 
observer.  For inclusion of minors the legal representative needed to consent the 
participation. 
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2.3.1.2 Screening procedure 
Patients admitted to HAS or CHRGR with symptoms suggestive of TB were 
identified during ward rounds. For these patients, screening for TB was done in 
collaboration with the CERMEL (i.e. sputum microscopy and culture was done at 
or via CERMEL, while chest x-rays were taken onsite). Study relevant information 
was copied from the patient file after obtaining the patient’s informed consent. 
Outpatients presenting to CTA with suggestive TB were identified during 
consultations. Consecutively, screening was done in collaboration between CTA 
and the CERMEL (i.e. sputum microscopy and culture was done at or via 
CERMEL, while chest x-rays were performed onsite). 
Outpatients at HAS and BELE, as well as patients seen directly at the CERMEL, 
who presented with suggestive TB were identified during consultations. 
Screening was done at the CERMEL (i.e. sputum microscopy and culture was 
done at or via CERMEL, chest x-rays were performed at HAS). 
After ascertaining study eligibility and obtaining informed consent, a 
questionnaire was used to assess essential demographics and the current and 
past medical history. A protocol-based detailed clinical examination was 
performed and the findings were recorded in a standardized way on a case record 
form (CRF).  
Diagnostic workup comprised the collection of sputum and blood samples for 
microbiological and laboratory analyzes, TST and chest x-ray examination. 
Further diagnostic investigations were performed if clinically indicated and 
initiated by the attending health care staff. If diagnostic measures had already 
been undertaken by the treating health facility before recruitment, the relevant 
information was copied from the patient file. All results of laboratory analyzes 
performed in the context of the study were reported back to the treating health 
facility.  
2.3.1.3 Sample collection 
Sputum samples were obtained during three consecutive days, ideally early in 
the morning. Samples from participants attended at HAS and CERMEL were 
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collected directly by a study clinician or a field worker and brought to the TB 
laboratory for further processing. Samples were collected in sterile screw topped 
containers without additives. 
Samples from patients attended at CHRGR, CTA and BELE were examined at 
the TB laboratory outside the study setting in cooperation between the TB 
laboratory and the health institutions. After recruitment of study participants and 
obtaining informed consent, their samples were later on assigned to them. 
Other samples eligible for mycobacteriology were pleural aspirates, lymph node 
aspirates, cerebrospinal fluid (from patients with suggestive EPTB) as well as 
gastric aspirates in children. Sample collection was done in the same way as the 
collection of sputum samples.  
Blood samples were taken from the patient by the study clinician and brought to 
the clinical laboratory of the CERMEL for serology, hematology and biochemistry 
analysis. 
2.3.1.4 Enrolment procedure 
Diagnosis of active TB and decision to initiate TB treatment was taken by the 
attending clinician of the respective health facility and based on the national TB 
guidelines [65]. All patients who were diagnosed with active TB and had given 
informed consent, were consecutively enrolled into the study and assigned a 
study identification (ID) number. 
2.3.1.5 Management of study participants 
Patients diagnosed with active TB were initiated treatment by the treating 
physician/nurse according to guidelines of the national TB program [65]. Study 
participants who underwent diagnostic TB workup at CERMEL only were referred 
to HAS for TB treatment. The treating health facility coordinated treatment and 
treatment supervision, while the study investigators recorded duration and form 
of treatment. 
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2.3.1.6 Follow up 
Follow up (FU) information was obtained two and six months (M2, M6) after 
initiation of TB treatment. In case of treatment extension decided upon by the 
attending physician, the FU period was extended until the end of the TB 
treatment.  
FU visit dates at the CERMEL were assigned to all patients, where a clinical and 
a mycobacteriological FU was scheduled. Outside of the study, patients had 
additional FUs at their respective health care institutions. Patients that missed a 
study FU visit were called on the phone by study staff. At least three attempts 
were made on different days to reach the patients. In case patients could not be 
reached on the phone FU information was looked up in the patients’ hospital file. 
In case no FU information could be retrieved from patient files at M6 FU, patients’ 
treatment outcome was classified as not evaluated. 
Collected FU information comprised data on medical history and current TB 
treatment. Treatment adherence was assessed by interviewing the participant on 
regular drug intake and treatment interruptions or reviewing the patient’s hospital 
file. In case of non-adherence, reasons for non-adherence and extent of non-
adherence were verbally investigated. Sputum smear and culture investigations 
were attempted for all patients at M2 and M6. Further diagnostic evaluations (e.g. 
laboratory, x-ray, etc.) during FU were done if adjudged to be clinically indicated 
by the attending health care staff. In case of a patient’s death, FU information 
was sought from patient files or by a verbal autopsy with the patient’s household 
members. 
The FU information was used to  
 Assess TB treatment outcome according to national and international 
definitions 
 Asses patients’ adherence to treatment and reasons for non-adherence 
 Detect acquired resistance of mycobacteria 
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2.3.1.7 Household visits and geo-referencing 
In the first weeks after study enrolment and treatment initiation, patients were 
visited at their homes by a field worker and/or a study clinician. The location of 
their residence was geo-referenced using the Garmin Dakota TM 20 GPS-device. 
A field worker explained the risk of transmission and the importance of contact 
screening to the patient and his household contacts. Household contacts were 
invited to come to the CERMEL for a TB screening examination and further 
diagnostics, if necessary. 
2.3.1.8 Acquisition on travel determinants 
In order to evaluate the impact of travelling from home to the TB treatment facility 
on TB treatment outcome, information about travel distance, duration and costs 
was assessed for each study participant.  
Travel distance was defined as the distance between the patient’s residence and 
the site of recruitment. If available, distance was calculated using the GPS 
coordinates taken during household visits. If no GPS coordinates could be 
obtained, distance was estimated using the patient’s reported residence.  
Travel duration was defined as the time patients needed to come to the hospital 
using public transport, such as taxi, boat or ferry. Information on travel duration 
was gained in an interview with local taxi drivers, using the patient’s description 
of his residence.  
Travel costs were defined as the fees for public transport, including taxi and boat. 
Information on costs was taken from the list used for compensation of travel 
expenses at the CERMEL. 
2.3.1.9 Interviews about TB treatment supervision and patient support 
To obtain a picture of TB treatment supervision and patient support, two 
questionnaires were done with a subset of study participants between September 
2013 and January 2014 . 
32 
 
 
 
One questionnaire on patient support aimed at assessing current practice of 
counseling, management of TB/HIV co-infection and duration of hospital 
admission in the view of patients. 
A questionnaire on treatment supervision aimed at assessing the setting and 
organization of control visits and measures to ensure treatment adherence.  
2.3.2 Laboratory procedures 
An overview of mycobacteriological study procedures is presented in Figure 2. 
 
Figure 2: Overview of mycobacteriological study procedures 
Time period: June 2012 – September 2014. ZN: Ziehl – Neelsen stain, FM: fluorescence microscopy, LJ: 
Löwenstein-Jensen agar, MGIT: Mycobacterium Growth Indicator Tube, PCR: polymerase chain reaction, 
M.tb.: mycobacterium tuberculosis, NTM: nontuberculous mycobacteria, DST: drug susceptibility testing, 
CERMEL: Centre de Recherches Médicales de Lambaréné, NRC: national reference laboratory 
2.3.2.1 Sputum smear examination by microscopy 
Sputum samples were analyzed by FM and by standard ZN staining. Precise 
procedures for preparation and staining of slides as well as for reading and 
reporting of results have been described by Siddiqi et al. [30]. 
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2.3.2.2 Microscopy of samples other than sputum (extrapulmonary) 
The procedures for microscopy of other samples were the same as for sputum 
smear microscopy. If the volume was over 10ml, concentration was done by 
centrifugation at 3000x g for 15-20 minutes before decontamination. 
2.3.2.3 Sample conservation, storage and shipment 
All samples for mycobacterial investigation were conserved and stored for 
shipment. During the first months of the study, specimens were conserved in 50% 
cetylpyridinium chloride; afterwards specimens were conserved without additive. 
Batched shipments to the NRC in Borstel, Germany, were done in intervals of 
four weeks. Shipment was organized through the international delivery services 
DHL and TNT, following packaging requirements for category B Biological and 
Infectious Substances (UN3373), it took around one week from sending to 
delivery. Samples were shipped at room temperature.  
2.3.2.4 Mycobacterial culture 
Sputum cultures were attempted for both smear positive and smear negative 
samples. Culturing of mycobacteria was done at the NRC in Borstel/Germany. 
Two parallel techniques, solid agar (Lowenstein-Jensen agar) and liquid culture 
tubes (MGIT) were used.  
A small volume of the decontaminated sample was inoculated onto two 
Lowenstein-Jensen medium slants and grown at 37°C. Growth was monitored 
visually twice per week for up to eight weeks, after which absence of growth was 
deemed as agar culture negative.   
In addition to the agar-based culture method, 500 uL of resuspended 
decontaminated sediment was used to inoculate a 4ml MGIT tube, and incubated 
in an automated BACTEC™ MGIT™ 960 Mycobacterial Detection System (BD 
Diagnostics, Belgium). Growth was recorded daily for five weeks [30]. 
2.3.2.5 Identification of M. tuberculosis complex 
The differentiation of mycobacteria and identification of the species was done at 
the NRC in Borstel/Germany. For differentiation between M.tb. complex and NTM 
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a Genotype MTBC assay (Hain Life Sciences, GmbH Germany) was performed 
on mycobacteria grown by culture. [66]  
2.3.2.6 Drug susceptibility testing 
Drug susceptibility testing (DST) was done at the NRC in Borstel/Germany. For 
all positive cultures identified as M.tb. complex, DST for the first-line 
antituberculous drugs (RIF, INH, EMB, PZA, STR) was performed. In case of any 
resistance to the first-line drugs except for STR, DST for the following second-
line drugs was performed: ETO, OFX, PAS, CS, AM and CM. 
Liquid culture DST was performed using the MGIT culture tube manual system 
according to the manufacturer’s  instructions  (BBLTM MGIT™  SIRE  and  PZA  
test  kits, Becton Dickinson) [30]. Testing of mycobacteria for susceptibility to INH, 
STR, RIF, EMB, PZA and to the above mentioned second-line drugs was based 
on the detection of growth in antibiotic-containing media compared to antibiotic-
free control tubes. 
The NRC reported results of culture, species identification and DST back to the 
study investigators at CERMEL via email on a weekly basis; the study 
investigators forwarded the results to the respective physicians on designated 
paper forms. 
2.3.2.7 HIV testing 
All patients enrolled in the study were strongly recommended to undergo HIV 
testing. If the testing had not yet been done by the treating health institution, 
patients were asked for their consent to assess their HIV status. For HIV testing 
patient sera were isolated from whole blood by centrifugation at 3000x g at 4°C. 
50μL of the patient’s sera were used to perform both the Determine HIV 1/2 
(Inverness Medical Innovations) and the Vikia HIV-1/2 (Standard Diagnostics, 
Kyonggi-do, South Korea) rapid diagnostic HIV tests. If both tests were in 
agreement with each other (both positive or both negative) the result was used 
as defining the patients HIV status. In case of a positive result, the patient was 
referred (back) to a local health institution for counseling and treatment. If the two 
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rapid diagnostic tests contradicted one another, a deciding third test was 
performed. This was done in the laboratory of HAS using a p24 Antigen test.  
2.3.2.8 Hematology and biochemistry 
Routine hematology and biochemistry analyzes were done either in the clinical 
laboratory of the CERMEL or at the laboratories of the recruitment sites. Since 
hematology and biochemistry results are not relevant for this thesis, they will not 
be further described in the following. 
2.4 Data management 
2.4.1 Data collection and storage 
All information about the study participants was collected on paper CRFs and 
kept as dedicated individual case files in the TB laboratory during the duration of 
the study. At the end of the study all study files were stored in the archive of the 
CERMEL. Only the study coordinator and designated study physicians and field 
workers had access to patient-identifiable information.  
2.4.2 Data entry 
Data collected on paper CRFs was entered into OpenClinica (OpenClinica® 
version 3.0.4, Boston, USA) and stored on the server of CERMEL. Data entry 
was done by the study field worker as well as designated data entry clerks and 
later verified by a study physician. Data of microbiology results such as culture, 
species identification and DST were entered in a Microsoft Excel spreadheet 
(Microsoft Corporation). 
2.4.3 Data cleansing 
After extracting data from OpenClinica in a Microsoft Excel worksheet, data 
cleansing was done as follows. Completeness of participants and variables was 
checked. Data of individual participants was checked and if possible, gaps were 
filled by querying the source data. Missing data was marked as such (not 
available (NA)). Consistency of available data was checked and microbiology 
data was added to the database. Free text entries were harmonized and 
standardized into categories. 
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2.4.4 Case definitions and definition of TB treatment outcomes 
Case definitions and definition of TB treatment outcomes were done according to 
the WHO [67] and Graham et al. [68] for adults and children younger than 18 
years, respectively. They are presented in Table 1. 
Table 1: Case definitions and definition of TB treatment outcomes 
* age below 18 years, + also if no information could be obtained directly from the patient himself and the 
patient was documented as LTFU at the treating health institution, TB: tuberculosis, WHO: World Health 
Organization, INH: isoniazid, RIF: rifampicin 
 Summary of Definition  
Adults (WHO [67]) 
Bacteriologically 
confirmed TB 
Positive microscopy or culture 
Clinically diagnosed TB Diagnosis by clinician or other medical practitioner 
Children* (Graham et al. [68]) 
Confirmed TB Microbiological confirmation 
Probable TB Chest x-ray consistent with TB and one of the 
following: Exposure to TB or positive TB treatment 
response or immunological evidence of TB 
Possible TB Chest x-ray consistent with TB or exposure to TB or 
positive TB treatment response or immunological 
evidence of TB 
TB unlikely Not fitting the above definitions 
Anatomical site (WHO [67]) 
Pulmonary TB Involving lung parenchyma or tracheobronchial tree 
Extra-pulmonary TB Exclusively involving organs other than the lungs 
History of previous tuberculosis treatment (WHO [67]) 
New TB No previous TB treatment 
Previous TB treatment Previous TB treatment for one month or more 
Relapse Previously declared cured or TB treatment 
completed 
Treatment after failure Most recent TB treatment failed 
Treatment after loss to 
follow up 
Lost to follow up at the end of most recent TB 
treatment 
Other previously 
treated patients 
Most recent TB treatment outcome unknown 
Patients with unknown 
previous TB history 
do not fit into any of the categories listed above 
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Table 1 (continued) 
Drug resistance (WHO [67]) 
Monoresistance Resistance to one first-line anti-TB drug only 
Polydrug resistance Resistance to more than one first-line anti-TB drug 
other than both INH and RIF 
Multidrug resistance Resistance to at least both INH and RIF 
TB Treatment outcome (WHO [67]) 
Treatment success  Total of “cured” and “treatment completed” 
Cured Smear or culture negative in the last month of 
treatment and on one previous occasion 
Treatment completed No evidence of failure but not meeting the criteria 
for “cured” 
Treatment failed Smear or culture positive at month 5 or later 
Died Death for any reason 
Lost to follow up Treatment interruption for two consecutive months 
or more+ 
Not evaluated Treatment outcome unknown 
Survival was documented if any information on the patient being alive at M6 +/- 
one month or later was available. Unfavorable treatment outcome was defined 
as outcome classification other than treatment success. 
2.5 Statistical analysis 
For statistical analysis data were extracted to a Microsoft Excel worksheet and 
then analyzed using R Statistical software version 3.1.3. (R Foundation for 
Statistical Computing, Vienna, Austria). The likelihood ratio test was used to test 
the linear trend for the continuous variables. Univariate logistic regression was 
used to calculate crude odds ratios with 95% confidence intervals. Stepwise 
selection with the Akaike Information Criterion was used to select the factors for 
the multivariate logistic regression model to calculate the adjusted odds ratios 
with 95% confidence intervals.  Using the Mantel-Haenszel method, confounding 
was investigated for risk factors with at least a 20% significant modification 
between crude and adjusted odds ratios.  Missing data analysis was performed 
and the database for variables with more than 15% missing data was completed 
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using multiple imputations by chained equations. Survival analysis was 
performed and Kaplan-Meir plots used for visualization. 
To assess the possible influences of travelling on treatment outcome the travel 
factor was calculated, which is a measure originally designed in the context of 
retention to HIV care (Janssen S, personal communication). Z scores (the 
number of standard deviations from the mean) were calculated from the three 
variables travel distance, duration and costs and later averaged to a single 
factor. Multivariate logistic regression was used to calculate the respective 
impact in treatment outcome. 
2.6 Ethical aspects 
The study was approved by the scientific review committee as well as the 
institutional ethics committee of CERMEL in June 2012. A notification about the 
study was given to the national ethics committee of Gabon. Participation in the 
TB epidemiology study was voluntary and written informed consent was obtained 
from all participant (section 2.3.1). All data collected was saved anonymously and 
patient files were kept in a secure room located at CERMEL. Samples were 
labeled anonymously (patient ID, date, type of specimen, study ID) preventing 
direct identification of the patient. 
Direct benefits for the patients participating in this study were comprehensive 
diagnostic procedures related to TB, which are only partly available on site in the 
routine setting. Active FU efforts by calling and inviting patients for FU supported 
patients in adhering to and completing their treatment. Another benefit was the 
free contact screening of study participants’ contacts. 
Indirect benefits were the capacity for TB diagnostics set up through the study, 
including FM, culture and DST in Lambaréné; these diagnostic tests were not 
previously available in the country. By systematically studying the local TB 
epidemiology this study supported the understanding of the most urgent needs 
to improve local TB care and control. Besides, this cohort study contributed to 
establishing a platform and network for future TB drug, TB vaccine, and new TB 
diagnostics trials all urgently needed to find quicker, safer and more effective 
39 
 
 
 
methods for detecting, treating and curing TB in Gabon, Central Africa and 
globally. 
2.7 Funding 
The study was supported by the European and Developing Countries Clinical 
Trials Partnership (EDCTP) through a grant to the Pan-African Consortium for 
the Evaluation of Antituberculosis Antibiotics (PanACEA) Consortium.  
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3 Results 
During the study recruitment period (from June 2012 to October 2013), 723 
patients submitted specimens to the TB laboratory for TB microscopy and culture. 
Additionally, 55 patients were clinically investigated for active TB without 
microbiological analyzes (patients unable to produce sputum). A total of 201 
patients with microbiologically or clinically diagnosed active TB and starting 
antituberculous treatment were enrolled; 103 (51.3%) were enrolled at HAS, 50 
(24.9%) at CHRGR, 28 (13.9%) at CERMEL, 15 (7.5%) at CTA, and 5 (2.5%) at 
BELE. 
3.1 Demographic, clinical and diagnostic findings 
3.1.1 Baseline demographics of the study population 
One hundred seventy (84.6%) patients were adults and 31 (15.4%) were children 
younger than 18 years. Twenty-five (12.4%) patients sought care for TB in 
Lambaréné despite other TB treatment centers being closer to their residency. 
Baseline demographic data including sex, age and HIV status are presented in 
Table 2. Travel determinants are presented in Table 3. 
Table 2: Baseline demographics of the study population 
Data collection period: June 2012 – October 2013, IQR: interquartile range, HIV: Human immunodeficiency 
virus, CD4: Cluster of differentiation 4, NA: not available, * Available for 200 patients, + Available for 51 (73% 
of HIV infected) patients, # living in villages or towns smaller than Lambaréné (around 30 000 inhabitants) 
 
 Total cohort Adults Children 
Total cohort (%) 201 (100) 170 (84.6) 31 (15.4) 
Female sex, n (%) 92/201 (45.8) 80/170 (47.1) 12/31 (38.7) 
Median Age, years (IQR)* 32.0 
(22.6;42.1) 
36.3 
(26.9;43.3) 
6.1 (2.0;15.4) 
HIV infected, n (%) 70/183 (38.3) 66/158 (41.8) 4/25 (16.0) 
New HIV diagnosis, n (%) 22/183 (12.0) 20/158 (12.7) 2/25 (8.0) 
Median CD4 counts, cells/µl 
(IQR)+ 
130 (56;227) 130 (56;227) NA 
Rural residence, n (%)# 69/201 (34.3) 61/170 (35.9) 8/30 (25.8) 
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Table 3: Travel determinants 
Data collection period: June 2012 – October 2013, TB: tuberculosis, IQR: interquartile range, FCFA: Franc 
de la Communauté Financière d’Afrique, * distance <5km represents living in Lambaréné, + available for 
148 adults and 30 children, # Available for 148 adults and 29 children,  
 
 Total cohort Adults Children 
Median distance to TB 
treatment center, km (IQR) 
3.6 (2.9;67.0) 3.7 (2.8;67.0) 3.6 (3.4;31.5) 
Distance < 5km, n (%)* 110/184 (59.8) 90/154 (58.4) 20/30 (66.7) 
Median travel costs, FCFA 
(IQR)+ 
500 
(400;3200) 
500 
(400;3450) 
500 
(475;2313) 
Median travel duration, 
minutes (IQR)# 
20 (15;60) 20 (15;60) 25 (20;30) 
3.1.2 Baseline characteristics related to TB 
Baseline characteristics related to TB (TB contact, symptoms, clinical findings, 
prior non-antituberculous antibiotics, chest x-ray findings, and TST) are 
presented in Table 4.  
Table 4: Baseline characteristics related to TB 
Data collection period: June 2012 – October 2013, TB: tuberculosis, NA: not available, SD: standard 
deviation, IQR: interquartile range, BMI: body mass index, TST: Tuberculin Skin Test, * Available for 58 
adults and 11 children, + Available for 143 adults and 21 children, # Available for 109 patients, ~ Percentiles 
provided by WHO: 3rd percentile for children <2 and 5th percentile for children >2 years 
 Total cohort Adults Children 
Total cohort, n (%) 201 (100) 170 (84.6) 31 (15.4) 
TB contact known, n (%) 72/189 (38.1) 48/160 (30.0) 24/29 (82.8) 
Main TB contact family member sibling parent 
Prior non-antitubercular 
antibiotics, n (%)  
74/113 (65.5) 65/98 (66.3) 8/14 (57.1) 
Most frequent antibiotics NA amoxicillin/ 
clavulanate 
ciprofloxacin 
cotrimoxazol 
gentamycin 
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Table 4 (continued) 
Reported TB symptoms 
Weight loss, n (%) 173/199 (86.9) 151/169 (89.3) 22/30 (73.3) 
Mean weight loss, kg 
(SD)* 
NA 8.0 (6.5) 3.7 (2.5) 
Cough, n (%) 167/200 (83.5) 143/170 (84.1) 24/30 (80.0) 
Fever, n (%) 162/198 (81.8) 138/169 (81.7) 24/29 (82.8) 
Night sweat, n (%) 100/194 (51.5) 88/168 (52.4) 12/26 (46.2) 
Chest pain, n (%) 76/200 (38.0) 69/170 (40.6) 7/30 (23.3) 
Hemoptysis, n (%) 44/197 (22.3) 43/168 (25.6) 1/29 (3.4) 
Dyspnea, n (%) 43/200 (21.5) 40/170 (23.5) 3/30 (10.0) 
Median duration of 
cough, days (IQR)+ 
30 (21;90) 30 (21;90) 26 (14;128) 
Clinical examination 
Pathologic lung 
auscultation, n (%) 
136/188 (72.3) 120/162 (74.1) 16/26 (61.5) 
Axillary temperature > 
37.5°C, n (%) 
77/162 (47.5) 71/142 (50.0) 6/20 (30.0) 
Lymphadenopathy, n (%) 36/188 (19.1) 28/160 (17.5) 8/28 (28.6) 
BMI, mean (SD)# NA 18.9 (2.8) NA 
Children < 3rd/5th 
percentile, n (%)~ 
NA NA 5/20 (25.0) 
Diagnostic findings 
Pathologic chest x ray, n 
(%) 
171/177 (96.6) 144/148 (97.3) 27/29 (93.1) 
Infiltrates, n (%) 144/177 (81.4) 122/148 (82.4) 22/29 (75.9) 
Cavitations, n (%) 56/177 (31.6) 51/148 (34.5) 5/29 (17.2) 
Hilar lymphadenopathy, n 
(%) 
55/177 (31.1) 43/148 (29.1) 12/29 (41.4) 
Pleural effusion, n (%) 21/177 (11.9) 19/148 (12.8) 2/29 (6.9) 
Positive TST, n (%) 36/58 (62.1) 26/41 (63.4) 10/17 (58.8) 
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3.1.3 Baseline mycobacteriology 
Baseline mycobacteriology (smear microscopy, culture, species identification and 
DST) is presented in Table 5. 
Table 5: Baseline mycobacteriology 
Sample collection period: June 2012 – October 2013, PCR: Polymerase chain reaction, TB: tuberculosis, 
MDR: multi-drug resistance, * Ziehl-Neelsen stain or fluorescence microscopy 
 Total cohort Adults Children 
Mycobacteriology 
performed, n (%) 
179/201 (89.1) 164/170 (96.5) 15/31 (48.4) 
Microscopy* and culture 
Sputum microscopy 
positive 
125/173 (72.3) 119/160 (74.4) 6/13 (46.2) 
Sputum culture positive 105/150 (70.0) 98/138 (71.0) 7/12 (58.3) 
Extrapulmonary 
microscopy positive 
1/10 (10.0) 1/8 (12.5) 0/2 
Extrapulmonary culture 
positive 
4/8 (50.0) 4/7 (57.1) 0/1 
Total positive 
mycobacteriology 
134/179 (74.9) 126/164 (76.8) 8/15 (53.3) 
Drug susceptibility testing and PCR 
M. tuberculosis, n (%) 89/108 (82.4) 83/101 (82.2) 6/7 (85.7) 
M. africanum, n (%) 17/108 (15.7) 16/101 (15.8) 1/7 (14.3) 
M. intracellulare, n (%) 2/108 (1.9) 2/101 (2.0) 0/7 
Drug sensitive TB, n (%) 88/105 (83.8) 82/98 (83.7) 6/7 (85.7) 
Mono-resistance, n (%) 7/105 (6.7) 6/98 (6.1) 1/7 (14.3) 
Poly-resistance, n (%) 2/105 (1.9) 2/98 (2.0) 0/7 
MDR, n (%) 8/105 (7.6) 8/98 (8.2) 0/7 
 
Sputa were available for 160 (94.1%) adults and 13 (41.9%) children. Sputum 
smear microscopy and culture was done from three, two and one sputa in 67.6%, 
23.1% and 9.2% patients, respectively. The positivity rate of sputum samples 
investigated by ZN microscopy was 63.2% and 36.4% for adults and children, 
respectively. The additional use of FM increased the positivity rate to 74.4% and 
46.2%, respectively. Due to temporary lack of reagents, some samples were 
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stained only either with ZN or for FM. Of patients who submitted one sputum only, 
14 out of 16 were positive. Cultures were performed for 166 (82.6%) patients, of 
which eight (4.8%) were contaminated. Of 125 microscopy positive patients, 17 
(13.6%) cultures were negative; of 48 microscopy negative patients, nine (18.8%) 
cultures were positive. Mean time span between sample collection and available 
culture results was 2.9 (SD 0.8) months. 
EPTB samples were investigated for eight adults and two children. Specimen 
from adults comprised four pleural fluids, two lymph node aspirates, one 
pericardial fluid, and one cerebro-spinal fluid. From children, one lymph node 
aspirate and one gastric aspirate were available. Of patients classified as EPTB, 
four (44.4%) were HIV-infected. 
DST was performed for 105 cultures and revealed drug resistance in 17 (16.2%) 
cases. Resistance pattern are presented in Table 6. Among culture confirmed TB 
patients the MDR-TB rate was 4/91 (4.4%) and 4/13 (30.8%) in new and 
previously treated TB patients, respectively. No XDR-TB was observed.  
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Table 6: Drug resistance patterns of mono-, poly- and multidrug resistant TB 
Sample collection period: June 2012 – October 2013, TB: tuberculosis, RIF: rifampicin, INH: isoniazid, PZA: 
pyrazinamide, EMB: ethambutol, STR: streptomycin, OFX: ofloxacin, ETO: ethionamide, CS: cycloserine, 
AM: amikacin, PAS: para-aminosalicylic acid, CM: capreomycin, R: resistant, S: sensitive, B: borderline, NA: 
Not available 
 First-line TB drugs Second-line TB drugs 
 R
IF
 
IN
H
 
P
Z
A
 
E
M
B
 
S
T
R
 
O
F
X
 
E
T
O
 
C
S
 
A
M
 
P
A
S
 
C
M
 
Mono-resistance to first-line drugs n = 7 
n = 2 S R S S S S S S S S S 
n = 1 S R S S S S R S S S S 
n = 1 S R S S S R S S S S S 
n = 3 S S S S R NA NA NA NA NA NA 
Poly-resistance to first-line drugs n = 2 
n = 1 S R S S R S S S S S S 
n = 1 S R S S R S R S S S S 
Multidrug-resistance n = 8 
n = 1 R R S R R S R S S S S 
n = 1 R R S R R R S S S R S 
n = 1 R R R R R S S S S S S 
n = 1 R R R R R S S S S S S 
n = 1 R R R R R S R S S S S 
n = 1 R R S R R S B S S S S 
n = 1 R R S S S S R S S S S 
n = 1 R R R R R S R S S S S 
 
3.1.4 Classification at treatment initiation 
Classification of TB patients by case definitions, anatomical site and history of TB 
treatment is presented in Table 7. 
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Table 7: Classification of TB patients according to WHO case definitions, 
anatomical site, and previous TB treatment 
Data/Sample collection period: June 2012 – October 2013, TB: tuberculosis, WHO: World Health 
Organization, NA: not available, LTFU: loss to follow up, * For two children data for classification based on 
anatomical site were not available 
 Total  
n = 201 
Adults 
n = 170 
Children 
n = 31 
WHO case definitions adults [67] 
Bacteriologically confirmed, n (%) NA 126 (74.1) NA 
Clinically diagnosed, n (%) NA 44 (25.9) NA 
Children according to Graham et al [68] 
Confirmed TB, n (%) NA NA 7 (22.6) 
Probable TB, n (%) NA NA 17 (54.8) 
Possible TB, n (%) NA NA 5 (16.1) 
TB unlikely, n (%) NA NA 2 (6.5) 
WHO classification based on anatomical site [67] 
Pulmonary, n (%) 190 (94.5) 161 (94.7) 29 (93.5) 
Extra-pulmonary*, n (%) 9 (4.5) 9 (5.3) 0 
WHO classification based on history of previous TB treatment [67] 
New TB, n (%) 165 (82.1) 140 (82.4) 25 (80.6) 
Previous TB treatment, n (%) 30 (14.9) 24 (14.1) 6 (19.4) 
Relapse, n (%) 13 (6.5) 11 (6.5) 2 (6.5) 
Treatment after failure, n (%) 3 (1.5) 3 (1.8) 0 
Treatment after LTFU, n (%) 11 (5.5) 8 (4.7) 3 (9.7) 
Other previously treated 
patients, n (%) 
3 (1.5) 2 (1.2) 1 (3.2) 
Patients with unknown previous 
TB history, n (%) 
6 (3.0) 6 (3.5) 0 
3.2 Antituberculous treatment and treatment outcome 
Most patients were treated by the health facility where they presented for 
diagnosis. Of those diagnosed at CERMEL most (22/28, 78.6%) were referred to 
HAS for treatment and five patients received treatment in prison coordinated by 
BELE. Follow-up data including clinical response to treatment and treatment 
adherence could be obtained for 120/201 (59.7%) and 80/183 (43.7%) patients 
at M2 and M6, respectively; follow-up continued beyond M6 for 48/181 (26.5%) 
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patients. Follow-up was done via phone call, face-to-face or by checking hospital 
files in 55.5%, 33.6%, and 11.5% of cases. Treatment outcomes by WHO 
definitions are presented in Table 8. 
Table 8: TB Treatment outcome according to WHO definitions [67] 
Data/Sample collection period: June 2012 – June 2014, TB: tuberculosis, WHO: World Health 
Organization, childr: children, HIV: human immunodeficiency virus, neg: negative, pos: positive, excl: 
excluding, MDR: multi-drug resistance 
 Total 
n = 201 
Total 
adults 
n = 170 
Total 
childr. 
n = 31 
Total 
HIV 
neg. 
n = 113 
Total 
HIV 
pos. 
n = 70 
Total 
excl. 
MDR 
n = 193 
Treatment 
success, n (%) 
107 
(53.2) 
91 
(53.5) 
16 
(51.6) 
65 
(57.5) 
30 
(42.9) 
106 
(54.9) 
Cured, 
n (%) 
15 
(7.5) 
13 
(7.6) 
2 
(6.5) 
10 
(8.8) 
4 
(5.7) 
15 
(7.8) 
Treatment 
complete, n (%) 
92 
(45.8) 
78 
(45.9) 
14 
(45.2) 
55 
(48.7) 
26 
(37.1) 
91 
(47.2) 
Treatment failed, 
n (%) 
6  
3.0) 
5 
(2.9) 
1 
(3.2) 
4 
(3.5) 
2 
(2.9) 
5 
(2.6) 
Died, 
n (%) 
21 
(10.4) 
20 
(11.8) 
1 
(3.2) 
1 
(0.9) 
20 
(28.6) 
17  
(8.8) 
Lost to follow up, 
n (%) 
34 
(16.9) 
26 
(15.3) 
8  
(25.8) 
21 
(18.6) 
12 
(17.1) 
34 
(17.6) 
Not evaluated, 
n (%) 
33 
(16.4) 
28 
(16.5) 
5 
(16.1) 
22 
(19.5) 
6 
(8.6) 
31 
(16.1) 
For 47/133 (35.3%) surviving patients for whom the precise TB drug regimen was 
documented, the treatment regimen deviated from the national TB guidelines in 
terms of treatment interruptions, inadequate drug combinations (following drug 
stock outs), imprecise timing of control visits, or incorrect drug dosage. At least 
seven patients stopped treatment directly after being discharged from the 
hospital. Of patients classified with treatment success 30/107 (28.0%) admitted 
any interruption of TB treatment with a median duration of 5 (IQR 2-14) days; 
treatment interruption or discontinuation occurred after a mean of 1.9 (SD 1.5) 
months. Most common reasons reported for treatment interruption or 
discontinuation were non-affordability of transportation costs (38.8%) and 
forgetting drug intake (28.6%); further reasons reported in decreasing frequency 
were subjective recovery, ignorance of the need to continue TB therapy, travel, 
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drug stock outs, family problems, side effects and immobility. Thirteen (9.4%) 
patients reported of consulting a traditional healer additionally to their standard 
TB treatment.   
At M2 and M6, 52 (57.8%) and 11 (19.0%) adult patients and six (27.3%) and 
three (25.0%) children still had any TB symptom, respectively. In adults remaining 
symptoms were mostly cough and fatigue, while in children remaining symptoms 
were mostly cough and fever. At M2 and M6, 67 (78.8%) and 52 (88.1%) adult 
patients had gained weight, respectively, with mean of 3.2 (SD 3.8) and 6.1 (SD 
6.0) kg. Among children, 18 (85.7%) and 10 (90.9%) had gained weight, 
respectively. 
Sputum was obtained at M2 and M6 from 46 (27.1%) and 30 (17.6%) adult 
patients and six (19.4%) and three (9.7%) children, respectively. Follow up 
sputum smear microscopy was done from three sputa in 74.6% and from two and 
one sputa in 11.9% and 13.5%, respectively. Of initially smear or culture positive 
patients 47/134 (35.1%) and 26/134 (19.4%) patients provided sputum samples 
at M2 and M6, respectively, and nine (19.1%) and two (7.7%) were still smear or 
culture positive at M2 and M6, respectively. Of seven smear or culture positive 
patients at M6 or later, one patient had been diagnosed MDR-TB at treatment 
initiation; one patient had received an under-dosed TB regimen; two interrupted 
treatment for more than two months; and for the remainder no treatment default 
was reported but could not be excluded. No initially sputum or culture negative 
patient became sputum or culture positive later on. No acquisition of MDR-TB 
was detected; one patient who retrospectively was on functional mono-therapy 
with PZA due to MDR-TB developed additional resistance to PZA within the first 
month of treatment. 
All patients whose cultures showed MDR-TB had been initiated on oral first–line 
TB drugs, three of them additionally had received STR for two months. M6 follow-
up information could be obtained for six of the eight MDR-TB patients: four 
patients had died, one patient was still on first-line TB treatment and one patient 
was taken off first-line treatment by M6. 
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3.3 Risk factors for unfavorable treatment outcome 
Risk factors for unfavorable treatment outcome are presented in Table 9. 
Table 9: Risk factors for unfavorable treatment outcome (n=193) 
Unfavorable treatment outcome defined as outcome classification other than treatment success and 
excluding patients with MDR-TB; linear trend for continuous variables tested by likelihood ratio test; crude 
odds ratios calculated by univariate logistic regression; factors for the multivariate logistic regression 
selected stepwise with Akaike Information Criterion; confounding investigated by Mantel-Haenszel method 
for risk factors with at least a 20% significant modification between crude and adjusted odds ratios; database 
completed using multiple imputations by chained equations for variables with more than 15% missing data. 
OR: odds ratio, CI: confidence interval, BMI: body mass index, TB: tuberculosis, * Very close < 3km; close 
3-15km; far ≥ 15km, + Adjusted on age, distance (groups), cavitation, confirmed clinical and HIV 
 
  Crude OR (95%CI) 
P-
value 
Adjusted OR+ 
(95%CI) 
P-
value 
Age 1 (0.98-1.02) 0.70 1 (0.96-1.05) 0.67 
BMI (kg/m2) 0.91 (0.78-1.05) 0.23 1.06 (0.85-1.31) 0.58 
Cough duration 1 (0.99-1.01) 0.21 1 (0.99-1.01) 0.17 
Gender 
Female Reference - Reference   
Male 0.80 (0.42-1.48) 0.47 1.08 (0.41-2.92) 0.86 
Distance* 
Very close Reference - Reference - 
Close 1.26 (0.56-2.80) 0.58 1.22 (0.34-4.23) 0.75 
Far 2.10 (1-4.44) 0.05 3.20 (1.10-9.90) 0.04 
Anatomy 
Extrapulmonary Reference - Reference - 
Pulmonary 2.45 (0.50-12.21) 0.27 5.48 (0.60-125.60) 0.18 
HIV 
Not infected Reference - Reference   
Infected 2.18 (1.10-4.36) 0.03 1.33 (0.47-3.67) 0.58 
Cavitation 
No Reference - Reference   
Yes 0.40 (0.20-0.80) 0.01 0.32 (0.10-0.98) 0.05 
Confirmed /clinical TB 
Confirmed  Reference   Reference   
Clinical 2.47 (1.08-5.64) 0.04 2.81 (1.03-7.92) 0.04 
New/retreatment TB 
Retreatment  Reference - Reference   
New 1.24 (0.47-3.26) 0.66 2.53 (0.50-15.30) 0.28 
 
50 
 
 
 
Risk factors for unfavorable treatment outcome were far distance to treatment 
center (>15km) (aOR 3.20, 95%CI 1.10-9.90, p 0.04), and clinical (not 
microbiologically confirmed) diagnosis of TB (aOR 2.81, 95%CI 1.03-7.92, p 
0.04). Risk factors significantly associated with death were HIV-infection (aOR 
6.93, 95%CI 1.62-29.70, p 0.02) and clinical (not microbiologically confirmed) 
diagnosis of TB (aOR 3.26, 95%CI 1.13-9.37, p 0.03); mean survival time of 
deceased patients was 53 (SD 50) days after treatment initiation. The only risk 
factor significantly associated with treatment default was long duration of cough 
prior to diagnosis (aOR 3.55, 95%CI 1.13-11.12, p 0.04). Survival analysis is 
presented in Figure 3. 
 
Figure 3: Survival analysis of TB patients (n=167) 
Data collection period: June 2012 – June 2014, patients without the date of death, loss of follow up or 
study end were excluded, TB: tuberculosis, MDR-TB: multi-drug resistant TB 
Risk factor analysis for unfavorable treatment outcome regarding the assessed 
travel determinants is presented in Table 10. The travel factor as proposed tool 
to investigate influences of travelling showed no significant correlation to 
treatment outcome. 
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Table 10: Influence of travel determinants on the risk of unfavorable TB 
treatment outcome (n=184) 
Unfavorable treatment outcome defined as outcome classification other than treatment success and 
excluding patients with MDR-TB; linear trend for continuous variables tested by likelihood ratio test; crude 
odds ratios calculated by univariate logistic regression; factors for the multivariate logistic regression 
selected stepwise with Akaike Information Criterion; confounding investigated by Mantel-Haenszel method 
for risk factors with at least a 20% significant modification between crude and adjusted odds ratios. 
TB: tuberculosis, OR: odds ratio, CI: confidence interval, * Adjusted on age, cavitation, confirmed clinical 
and HIV, + the number of standard deviations from the mean, # equates to the proposed travel factor 
 
  
Crude OR 
(95%CI) 
P-
value 
Adjusted OR* 
(95%CI) 
P-
value 
Z-score+ for distance 1.13 (0.82-1.57) 0.44 1.05 (0.71-1.56) 0.77 
Z-score for time 1.01 (1-1.01) 0.17 1.16 (0.81-1.67) 0.41 
Z-score for cost 1.28 (0.90-1.83) 0.17 1.47 (0.98-2.23) 0.07 
Average of three Z-
scores# 
1.02 (0.99-1.04) 0.16 1.01 (0.98-1.05) 0.33 
3.4 Counseling, patient support and treatment supervision  
Twelve patients were interviewed concerning counseling and patient support. 
The results are presented in Table 11. 
Nine patients were interviewed concerning treatment supervision. The results 
are presented in Table 12 
. 
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Table 11: Interviews regarding counseling and patient support (n=12) 
Data collection period: September 2013 – January 2014. Patients interviewed were treated at the internal 
medicine department of HAS (9 patients) and CHRGR (3 patients). 
TB: tuberculosis, HIV: human immunodeficiency virus, NA: not available 
Counseling HIV care 
“Who told you that you suffer from 
TB?” 
“Have you been tested for HIV at TB 
diagnosis?” 
a doctor 10 yes 10 
a nurse 1 previously known HIV infection 2 
diagnosis unknown 1   
“When have you been told to have 
TB?” 
“Who informed you about your HIV 
status?” 
before TB treatment initiation 8 a doctor 8 
after TB treatment initiation 2 a nurse 2 
NA 2 NA 2 
“Did you have the possibility to ask 
questions when you were told to have 
TB?” 
“Is HIV care available at the same 
institution treating you for TB?” 
yes 8 yes 3 
no 2 no 1 
NA 2 NA 8 
Hospitalization 
“Were you admitted to the hospital at 
the beginning of TB treatment?” 
“How many days were you admitted?” 
yes 12 mean duration, days 
range (n) 
13 
10-15, 11 
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Table 12: Interviews regarding treatment supervision (n=9) 
Data collection period: September 2013 – January 2014. Patients interviewed were treated at the internal 
medicine department of HAS (4 patients) and CHRGR (4 patients) and at the pediatric department of HAS 
(1 patient). 
TB: tuberculosis, excl: excluding, NA: not available, FCFA: Franc de la Communauté Financière d’Afrique 
Treatment supervision 
“How many control visits did you 
attend so far?” 
“How many days did the control visits 
take?” 
two 2 one 5 
four 2 two 3 
five 2 three 1 
six 3   
“How long were the intervals between 
consecutive control visits?” 
“Did you attend all control visits at the 
date scheduled?” 
a) during the intensive phase: yes 6 
30 days 9 no 3 
b) during the continuation phase: “If no, why not?“  
30 days 4 no transport to clinic available (1) 
not been received in clinic (1) 
unaffordable transport costs (1) 
60 days 3 
NA 2 
“Have the control visits always been 
done by the same physician?” 
“On average, how much did you pay 
for a control visit (excl. transport)?” 
yes 4 mean costs, FCFA  9,222 
no 5 range (n) 0 - 30,000 (9) 
“Did you receive a log for the 
documentation of your TB treatment?” 
“Did your treating physician call you 
on the phone to remind you of a 
control visit?” 
yes 3 yes 2 
no 6 no 7 
 
  
54 
 
 
 
4 Discussion 
Panepi was the first systematic prospective cohort study on clinical and 
microbiological aspects of TB in Gabon, a middle-income country in Central Africa 
ranking among the top ten countries in terms of TB incidence per population in 
2013.  
4.1 Demographic, clinical and diagnostic findings 
4.1.1 Age considerations 
The median age of 36 years and a trend towards more male patients (53%) 
among adult TB patients was in line with previous reports from Gabon [5, 7, 69] 
and the WHO [3]. 
Commonly, adult and pediatric TB patients are not considered within the same 
cohort as many aspects around TB differ between adults and children. This study 
however chose a comprehensive approach to gain a cross-sectional insight into 
all services that care for TB patients in the region. Incidence rates of childhood 
TB have been reported to depend on the overall TB incidence in the population, 
and the proportion of TB cases among children may increase to 40% where 
incidence is 1,000 per 100,000 population [14]. The proportion of 15% of 
childhood TB in this cohort (especially given the cut-off of <18 years for childhood 
TB) may under-represent the true burden in the pediatric population; the 
uncommonly high positivity rate of sputum smear microscopy further underlines 
the assumption that microbiology negative pediatric TB patients are under-
recognized and missed. The proportion of 4% of pediatric TB cases officially 
notified in Gabon [4] certainly reflects significant under-recognition and/or 
reporting of childhood TB. 
4.1.2 High HIV co-infection rate 
The HIV/TB co-infection rate of 38% in patients with known HIV status was 3.5-
fold higher than reported by the WHO in the 2013 country profile (11%) [4], higher 
but closer in line with reports from retrospective studies evaluating TB patients 
hospitalized in the capital Libreville (26%-32% in 2001-2010) and Lambaréné 
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(34% in 2007-2012) [5-7, 69] and similar to a recent report from Cameroon [70]. 
The true HIV/TB co-infection rate may be even higher as for almost 10% of 
patients the HIV status could not be ascertained. Every tenth patient presenting 
with TB was newly diagnosed with HIV-infection underlining the importance of the 
current WHO guidelines that every TB patient should be tested for HIV. During 
the study period, all patients who were newly diagnosed TB at the internal 
medicine department of HAS and CHRGR received HIV testing at their respective 
health facility. Overall, CD4 cell counts of HIV-infected patients were low at 
presentation  with median 130 (IQR 56; 227) cells/µl; 37/56 (72.5%) patients were 
in a state of severe immunosuppression [71] or CDC category 2 [72], making 
them prone to progression of TB disease. 
4.1.3 Typical clinical presentation 
Weight loss, cough and fever were the three most common TB symptoms 
reported; a quarter of patients reported hemoptysis, a rate generally in line with 
the varying rate ranges reported [73] but much higher than reported in a 
retrospective study from an urban cohort in Gabon [69]. In patients with 
hemoptysis but lack of microbiological confirmation of TB from sputum (5% of 
patients in this cohort) paragonimiasis, a parasitosis that shares similar clinical 
manifestations with pulmonary TB and has repeatedly been reported endemic in 
Gabon [74-78], should be considered as differential but was not investigated for. 
For other co-endemic regions it has been proposed that routine exclusion of 
paragonimiasis be carried out as the costs of incorrect diagnosis and treatment 
may be significant [79]. 
4.1.4 Reliable quality of diagnostics 
In Gabon the only implemented TB diagnostic tool for microbiological 
confirmation of TB is smear microscopy by ZN. The gradual replacement of ZN 
technique by FM using light-emitting diode lamps, recommended by the WHO in 
2009 based on improved sensitivity and reduced workload [29], has not been 
introduced in Gabon. This study was the first to evaluate FM in this setting and 
FM performed superior to the ZN technique by increasing the sputum positivity 
rate by 10%. While the overall benefits of FM outweigh ZN technique and FM 
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technique is readily picked up after short training, breakdown of electrical parts 
including lamps of FM is a concern [80], this needs to be considered before a 
general roll out of FM as in Gabon respective maintenance service and access 
to replacement parts is not established. 
Mycobacterial culture and molecular diagnostics are not yet routinely available in 
Gabon. For this study mycobacterial cultures were performed overseas requiring 
storage and shipment of samples which may have impacted the results. The 
culture contamination rate of <5% was acceptable compared with other studies 
[81, 82], and positive cultures in some patients with negative microscopy reflect 
the expected higher sensitivity of culture compared to microscopy; Decreased 
viability following either unreported intake of TB drugs prior to sampling or sample 
storage and shipment may however have led to false negative culture samples. 
4.1.5 High rate of microbiological confirmed TB 
Two thirds of adult patients had microbiologically confirmed TB, a rate 
comparable to the retrospective study from Lambaréné [5] but higher than 
reported in retrospective studies from the capital [7, 69]. Since the population of 
this study profited from intensified case finding through fluorescence microscopy 
and culture the higher rate might be closer to the real value. On the other hand, 
as health care levels between Lambaréné and the capital differ, establishing 
diagnosis of microbiologically negative TB may be more challenging for 
physicians in Lambaréné and microbiologically negative TB cases may be 
missed.  
4.1.6 Low rate of EPTB 
Unexpectedly few (<5%) patients were diagnosed with exclusive EPTB. In 
settings with high HIV prevalence EPTB may account for a considerable part of 
the total TB burden and in previous retrospective report from Gabon EPTB 
accounted for 20%/15% and 39%/35% of TB cases in HIV-uninfected and HIV-
infected hospitalized patients, respectively [5, 69]. Therefore under-diagnosis of 
EPTB in this cohort is highly probable. A recent report on inpatients from 
Cameroon with a similar TB/HIV co-infected rate found EPTB without concurrent 
PTB in 35% [70]. Interestingly, no difference in the rate of EPTB in HIV-infected 
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versus uninfected patients was reported in one previous study from Gabon and 
other factors than HIV accounting for higher susceptibility for TB in the Gabonese 
population, e.g. alcohol consumption or other infectious diseases, were 
postulated [69]. The eminent health concern of EPTB and the pronounced 
difficulties with its diagnosis are increasingly recognized [83]. Implementation of 
point-of-care focused assessment with sonography for HIV-associated TB 
(FASH) has been reported to improve diagnosis of EPTB in adult patients with 
HIV infection in resource-limited settings [84, 85]. Awareness and knowledge on 
EPTB needs to be increased in the setting of this study and implementation of 
FASH may contribute to improved diagnosis and care of EPTB [86]. 
4.1.7 High prevalence of M. africanum 
Mycobacteria other than M. tuberculosis were isolated in 18% of patients. M. 
africanum, a subspecies within the Mycobacterium tuberculosis complex and only 
endemic in West African countries, had a prevalence of 17.5% in this Gabonese 
cohort. While M. africanum has never been reported from Gabon, in neighboring 
Cameroon its prevalence was previously reported with 56% 30 years ago (based 
on biochemical speciation) [87] and more recently reported with 9% using 
molecular methods [88]. In the Gabonese cohort M. africanum infection was not 
associated with HIV-infection nor with outcome of TB treatment. M. africanum 
generally responds to regular TB treatment [89] therefore its high prevalence in 
Gabon does not require local treatment adaption; however, resistance pattern 
must be monitored carefully as 12% (2/17) of isolates showed INH resistance 
plus OFX or STR and ETO resistance, respectively. 
4.1.8 High rates of drug resistant TB among previously treated TB 
patients 
Given previous anecdotal report on MDR and XDR-TB [13], the limited availability 
and access to DST and TB drugs [90] and low treatment completion rates [4] in 
Gabon, concerns about the prevalence and extent of DR-TB were high. With 
4.4% and 30.8% of MDR-TB in new and previously treated patients the MDR-TB 
rates exceeded the overall global rates reported with 3.5% and 20.5% for 2013 
by the WHO [3]. As DST was only performed for half of the cohort, the true rate 
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of DR-TB may be higher or lower; continuous surveillance data are needed to 
better understand the epidemiology of DR-TB in Gabon. 
4.2 Antituberculous treatment and treatment outcome 
The overall treatment success rate was concerningly low with 53% which is far 
from the WHO target treatment success rates of 85%. Given the research 
framework of this study with designated human and laboratory resources, the true 
treatment success rate outside of this research setting must be estimated even 
lower. 
Only 8% of patients could be classified as cured according to the WHO 
guidelines. This low rate can be attributed to the increased efforts required from 
both the patients and the health institutions to gain enough specimen during the 
follow up period to declare a patient cured, exceeding the capabilities in a 
resourced-limited setting such as Lambaréné. The rate of patients routinely 
undergoing microbiological control examinations must be considered to be even 
lower than in the context of this study (27.1% and 17.6% at M2 and M6, 
respectively), taking into account the active follow up strategy applied by the 
study in terms of reminding patients of FU visits and supporting logistics and costs 
related to diagnostic FU. 
Loss to follow up was the most common reason for adverse treatment outcome. 
The LTFU rate of 17% was lower than previously reported by studies from 
Lambaréné and the capital [5, 91]; the lower rate in this cohort might have been 
biased by the active follow up strategy applied by the study. Furthermore, the 
portion of patients whose treatment outcome could not be evaluated (16%) 
probably harbors patients actually being LTFU. Of concern, for at least more than 
a third of all patients, including those classified as treatment success, deviations 
from the recommended TB treatment regimens were documented.  
The death rate of 10% was twice as high as suggested by previous studies from 
Gabon [5, 7]. The higher rate might as well be explained by the active follow up 
strategy employed in this study; probably patients are often classified as LTFU if 
59 
 
 
 
they do not come back to the hospital but in this study calling patients’ relatives 
allowed for documenting death as a reason for not presenting for FU visits. 
For the first time in Gabon, treatment failure was investigated for and the rate of  
3% is in line with a recent study from Cameroon [92]. However, the lack of DOTS 
outside the hospital makes it impossible to reliably distinguish treatment failure 
from default. 
Among children, the high rate of patients LTFU equally points towards 
deficiencies in patient support and treatment supervision, consistent with the 
global experience of childhood TB being neglected in the fight against TB [14]. 
Children are a vulnerable group of patients and depend on their caregivers for 
successful treatment completion; implementation of DOTS for children may 
require a person other than the direct caregiver to be responsible for treatment 
supervision. 
Established risk factors such as male sex [61, 62, 93-95] and malnutrition [63, 64] 
did not show significant correlation with default and death in this study. This might 
be explained by the limited cohort size of the study. Further research is needed 
in order to rule out gender differentials and nutritional components as reason for 
low treatment success. 
4.3 Barriers towards successful treatment 
4.3.1 Drug resistant TB 
Treatment outcomes of the eight MDR-TB patients in this study could not be 
classified according to WHO guidelines since intake of appropriate second-line 
treatment is a condition for such outcome classification; at the time of the study 
no second-line TB drugs were available in Gabon and none of the MDR-TB cases 
therefore received appropriate treatment. Half of the MDR-TB patients died 
during the study period, this would have been preventable in a setting where 
MDR-TB patients had access to appropriate care. As surviving MDR-TB patients 
were not receiving appropriate treatment and continued to live within their 
communities spreading of MDR-TB to further individuals is highly probable; this 
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situation of uncontrolled MDR-TB depicts a major public health threat and impairs 
successful TB control on a regional and national level.  
All MDR-TB isolates had further resistance; all but one showed additional 
resistance to EMB and STR and half were resistant to PZA. Therefore, for most 
MDR-TB cases no first-line antituberculous drugs were left as partner drugs for a 
second-line treatment. Concerning second-line drugs almost half of the isolates 
were resistant to or had reduced susceptibility to ETO and two isolates showed 
any second-line drug resistance other than to ETO. The high rate of ETO 
resistance may be related to the high rate of INH resistance as both drugs share 
common pathways which can lead to cross-resistance [96] but further molecular 
analyzes are required to elucidate this. 
Among mono- and polyresistant TB strains, INH and STR showed the highest 
rates of resistance (among isolates with any drug resistance 82% and 76%, and 
among all isolates with DST 13% and 12%, respectively). INH is the cornerstone 
of first-line antituberculous therapy, INH mono-resistance reduces the probability 
of treatment success if standard treatment is administered and increases the risk 
of acquiring additional resistance and thereby MDR-TB [97]. Importantly, in 
countries with high HIV prevalence INH resistance renders IPT ineffective and 
hampers prevention and control of HIV-associated TB. INH resistance and 
effectiveness of IPT in Gabon should be carefully monitored. As almost half of 
patients with previous TB treatment and 7/8 patients with MDR-TB had STR 
resistant TB, the current local guidelines recommending addition of STR to the 
four oral first-line antituberculous drugs for previously treated TB patients may 
need revision 
One of the biggest challenges in the fight against MDR- and XDR-TB is the 
worldwide availability of affordable and quality-assured second-line drugs. During 
the last decade, the global framework to support expansion of MDR-TB services 
and care (green light committee initiative) has made considerable progress and 
90 countries and 130.000 patients had received aid in 2011 [98]. However, 
neither guidelines for diagnosis or second-line regimens nor access to second-
line drugs to treat DR-TB existed in Gabon at the time of conducting this study. 
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Furthermore, there is widespread usage of antibiotics (probably including 
potential second-line Tb drugs) without prescription among TB patients due to 
misinterpretations of symptoms and drug stock outs [90, 99]. Decentralized TB 
treatment centers with different health care staff lacking specialized TB training 
and initiating TB treatment promotes incorrect TB treatment prescriptions [90, 99]. 
All these factors fuel the development of resistance against first- and second-line 
drugs [100]. 
4.3.2 HIV co-infection 
In this study HIV co-infection was the most significant risk factor for death. 
Treatment success rates are significantly lower in HIV-infected patients on a 
global level and in the African region; in 2012, the global treatment success rate 
was 74% compared to 88% and death rate was 11% compared to 3.4% in HIV-
infected and HIV-uninfected patients respectively [11]. In Gabon, increased rates 
of LTFU have been described in HIV patients coinfected with TB (Janssen S, 
personal communication). Reasons for adverse treatment outcome and death 
include TB-related conditions such as disseminated TB, immune reconstitution 
inflammatory syndrome and treatment side effects as well as non TB-related 
conditions [101, 102]. However, predominant reasons for death in TB/HIV co-
infected patients differ between various regions related to the level of TB and HIV 
care [103, 104]. Further research is needed to identify reasons for death in 
TB/HIV co-infection in Gabon. 
As further data on HIV care has not been comprehensively collected in this study, 
detailed additional determinants of HIV infection, ART and IPT or cotrimoxazol 
prophylaxis cannot be reported. Limited data from this study and other reports do 
however suggest that in Gabon uptake of ART, retention to care, IPT and 
integrated TB/HIV care are still to be improved (Janssen S, personal 
communication) [4]. At the time of the study, no integrated HIV/TB care was 
possible at CHRGR, endangering outcome of both TB and HIV treatment [105-
107]. 
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4.3.3 Geographical barriers 
Far distance to the TB treatment center was identified as a statistically significant 
risk factor for unfavorable treatment outcome. This is in line with qualitative 
research on malaria prevention and vaccinations in Gabon, which reported 
distance to the hospital as a risk factor for non-adherence; explanations include 
constraints due to field and house work, long queues and limited reception times 
at the hospital [108, 109]. Studies on TB treatment outcome from Nigeria, Nepal 
and India reported similar findings [60, 62, 110] but could show at the same time 
how implementation of DOTS and the use of peripheral and ambulatory treatment 
options were able to increase the rate of successfully treated TB [62, 110]. 
The travel factor as proposed tool to investigate influences of travelling showed 
no significant correlation to treatment outcome in this study, which is probably 
due to a limited cohort size. However, comparison of the three Z-scores for travel 
distance, duration and costs showed a trend of the latter having the greatest 
influence on treatment outcome, which is in line with other findings of this study 
(section 4.3.6). 
4.3.4 Atypical presentation of TB 
Clinical diagnosis of TB without microbiological confirmation (including smear 
negative pulmonary and EPTB) was identified as risk factor for unfavorable 
treatment outcome. The most likely explanation is the high rate of HIV co-
infection, with HIV being a well-established cause for TB disease dissemination 
and smear negativity as well as higher death rates [69, 70, 111]. However, after 
adjusting analyses for HIV status, the correlation remained significant, suggesting 
other reasons to account for inferior treatment outcomes.  
Possible explanations include misdiagnosed TB in patients suffering from other 
diseases such as paragonimiasis (section 4.1.3), delayed case finding and 
treatment initiation with consecutive disease progression [112] and different 
disease perception in unconfirmed TB with a higher risk of default and death  [99] 
(section 4.3.8). 
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4.3.5 Delay in treatment initiation 
Long duration of cough was a risk factor for default in this study. Patients 
presented late with half of the patients coughing for at least one month and a 
quarter for at least months. Reasons for late presentation in Gabon and 
Cameroon were suggested to be stigma, costs and the use of traditional medicine 
[113, 114]. Apart from inferior treatment outcome, late presentation and delay in 
diagnosis of pulmonary TB also translates into increased infectivity in the 
community; inacceptable time delays across high and low income countries are 
still a widespread problem and a major challenge for effective TB control [115].  
4.3.6 Economic barriers 
The most common reason for deviation from treatment named by the patients in 
this study was the unaffordability of transportation costs (38.8%), which is in line 
with results from a study performed in Libreville in 2006 [91]. Interviews on travel 
costs showed that a quarter of patients had to pay more than 3,500 FCFA per 
way, which is more than the estimated daily family income for big parts of the 
local population [116]. Furthermore additional costs of up to 30,000 FCFA 
became due for the payment of x-rays and additional examinations during control 
visits. 
The connection between poverty and TB is established for a long time [117]. The 
burden of direct and indirect costs by TB disease has been shown to be a 
challenge worldwide, and particularly in African countries [57, 58]. While Gabon 
is a comparably rich country in central Africa, people in rural areas are often not 
sharing the country’s wealth. In 2005 a third of the Gabonese population lived 
below the national poverty line [118]. The fact that the PNLTB is generally 
providing free TB medication is mostly not known in the population [99]. 
Remarkably, in Gabon a health insurance has been established since 2008, 
covering 80% of the costs falling due for in-hospital treatment. However, no other 
TB related costs are reimbursed by the insurance and it is not yet clear if this 
development has made a change [119]. 
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4.3.7 Stigma 
Of note, the designated TB clinic in Lambaréné saw the fewest TB patients and 
every tenth patient sought care for TB in Lambaréné despite other TB treatment 
centers being closer to his residency. Additionally, an over-average proportion of 
patients presents with pronounced delay. These observations may point towards 
TB patients preventing to be recognized and stigmatized as suffering from TB, or 
patients being unaware of their possible disease preventing their direct 
presentation to TB care services. Travelling long distances to avoid stigmatization 
in the environment of daily living has been reported for a subgroup of HIV patients 
cared for in Lambaréné (Janssen S, personal communication). In an 
anthropological study, 67% of patients reported to feel problematically 
stigmatized in Lambaréné, partly due to double stigma with TB/HIV [99]. 
4.3.8 Alternative treatment approaches 
As recently shown by an anthropologic study performed within a proportion of this 
study’s population by Cremers et al, pluralistic health treatment (i.e. the use of 
various treatment approaches, such as hospitals, pharmacies, herbal medicine, 
religious and traditional healers) is common in Gabon and in most cases patients 
seek different treatment options before coming to the hospital. Local perceptions 
of TB differentiate between magical disease (vampires, poison or demons and 
not responding to conventional drug treatment) and natural disease. Negative 
microbiological examination results for TB often prompt patients to believe 
suffering from magical instead of natural TB, probably enhancing treatment 
default [99].  
Interestingly, while widespread consultation of traditional healers was shown 
using the in depth-interviews of the anthropologic study, only 9% of participant 
had made use of such consultations according to the questionnaires employed 
by this study. This discrepancy might point towards a competing nature of 
traditional and hospital medicine in Gabon, making patients hide their preference 
of alternative treatment from hospital staff and researchers.  
On the other hand, Cremers et al reported of the combined use of traditional 
healers and hospital treatment by patients, despite no interaction between 
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tradition healers and hospital staff seems to exist [99]. Interestingly, some 
concepts of traditional medicine show parallels to hospital medicine, like the 
initiation rites capable of preventing diseases resembling disease prophylaxis, 
e.g. in form of vaccinations.  
Herbal treatment is easily accessible also in remote areas. Although the 
widespread usage of herbal medicine in Gabon is no uncommon finding [120], 
little is known about its effect and side effects and further investigation is needed 
in order to assess its influence on TB treatment outcome. 
4.3.9 Lack in counseling, patient support and supervision 
Problems arising from the variety of competing official and unofficial health care 
providers are amplified by the lack of patient support and treatment supervision 
by the hospitals. The interviews on counseling and patient support point towards 
several deficiencies in the support of newly diagnosed TB patients, these include 
insufficient attending to patients’ concerns and a missing concept regarding time 
and content for counseling. Similar deficiencies have recently been found 
regarding counselling in HIV care in Lambaréné (Janssen S, personal 
communication). 
Equally, several deficiencies in treatment supervision became evident, such as 
the lack of a treatment log for patients and long intervals between control visits of 
up to 60 days during the continuation phase, which is far from directly observed 
treatment. Effectively, DOTS was only performed during hospital admission, 
which on average lasted 13 days. 
The fact that “forgetting drug intake” and “subjective recovery” was reported 
among the three most common reasons for treatment interruption or 
discontinuation in this study, supports the assumption that patients were not given 
enough information and education regarding their disease and the required 
treatment. 
4.4 Overcoming the barriers 
Several deficiencies in Gabonese health care structure became evident through 
this study. Strategies, concepts and recommendations for addressing these have 
66 
 
 
 
been established and proved efficient in other settings; respective 
implementation in Gabon is discussed in the following sections.  
4.4.1 Patient centered TB care and DOTS 
Integrated, patient centered care and prevention is one fundamental pillar of the 
WHO post-2015 global strategy in the fight against TB [3]. While other regions 
have successfully adopted the DOTS strategy since more than a decade [121-
123], DOTS expansion and enhancement is urgently needed in Gabon. Currently 
DOTS is not performed outside the hospital and due to high mobility, alternative 
treatment seeking behavior and financial considerations, patients in remote rural 
areas of Gabon are in increased risk of defaulting. In a recent systematic review 
and meta-analysis it was shown that default rates are lowest when DOTS is used 
throughout treatment. Suggested steps towards DOTS implementation have 
been decentralization of health services with limiting of cohort sizes, training of 
community health workers, involvement of family members and the use of patient 
registration forms [53, 124]. 
Patient health education needs to be an inherent part of counseling and treatment 
supervision and to be additionally offered to people living in remote areas by 
community health workers in order to foster compliance and reduce stigma. 
Traditional and religious perceptions should not be neglected but instead be 
specifically addressed in health education [125]. 
Interaction between traditional healers and hospitals is needed in order to lower 
competition between health services and to fall back on the network and the 
confidence traditional healers enjoy in the population [126-128]. Research is 
needed on prospects and dangers of traditional and herbal medicine. 
Childhood TB must be addressed specifically by raising awareness in the 
population and by offering improved patient support and treatment supervision 
among hospital staff. Additional diagnostic methods such as gastric aspirates and 
induced sputum [129] need to be established in pediatric departments to not only 
enhance case finding but also ensure treatment success. 
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4.4.2 Fight against MDR-TB 
As MDR-TB does not respect geographical borders, the spread of MDR-TB in 
Gabon needs to be stopped in time to prevent development of a breeding ground 
endangering TB control in the central African region and the whole world. 
The five priority actions to address the MDR-TB epidemic by the WHO (high-
quality treatment of drug sensitive TB to prevent DR-TB, expansion of rapid 
testing and detection of MDR-TB, immediate access to quality care, infection 
control, and increased political commitment) [3] are important for Gabon. Through 
the efforts of this study and related infrastructure set-up, a TB laboratory with the 
capability of performing mycobacterial culture and DST has been established and 
application to the Greenlight Committee for second-line drugs has been 
submitted. Country wide access to culture and DST as well as second-line drugs 
is urgently needed; 
4.4.3 Integration of HIV and TB care 
Other regions affected by high rates of TB/HIV co-infection have pioneered and 
demonstrated effective measures in the fight against the co-epidemic [9]; In 
Gabon, despite progress made within the last decade, mortality of TB/HIV co-
infection is still unacceptably high and further work on the integration of HIV and 
TB care is necessary. Integrated services need to be implemented in all hospitals 
to allow for early detection of TB and provision of IPT among people living with 
HIV as well as early initiation of ART among patients with HIV-associated TB [3, 
9]. Further steps are the improvement of home-based care including the training 
of volunteer caregivers and family education on infection control. [130] 
4.4.4 Addressing the social determinants of health 
In order to achieve a sustainable TB care in Gabon and regarding the high efforts 
needed to achieve the global targets set for 2030 [52], the implementation of 
DOTS is not sufficient. Upstream factors for health care deficiencies must be 
addressed. These include social determinants of health such as the weak and 
inequitable social policy, making the health system prone to corruption. Likewise, 
the ongoing uncontrolled urbanization leads to overcrowded slums and 
overburdened health care services, therefore hampering TB control [59]. National 
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and global efforts must be directed towards these problems in form of social 
protection and urban regeneration. 
4.4.5 Research 
The WHO global post-2015 strategy comprises intensified research and 
innovation as one of three fundamental pillars. This includes not only the 
development of novel tools in the fight against TB but also research on 
implementation and impact of already existing tools and strategies [3]. In the 
Central African region data on the extent of TB/HIV coinfection and the coverage 
of ART and IPT are scarce and research is needed to evaluate integration of TB 
and HIV care [131]. In Gabon, further research is needed to understand reasons 
of adverse treatment outcome. The newly established national reference 
laboratory will allow closer insight on the characteristics and dynamics of DR-TB 
in Gabon. Prospective TB studies must be performed in the big cities of Gabon 
in order to gain a clearer picture of the national TB situation. Moreover, studies 
on specific groups in the population suffering from TB are necessary, such as 
children and prisoners.  
4.5 Limitations 
This study has some limitation. Due to the observational character and the 
responsibility of care being with various health care staff, data collection and 
documentation was sometimes incomplete. On the other hand the observational 
design of the study is more likely to reflect the true situation in the field; however, 
human and laboratory resources provided through the study may also have 
influenced the observations in terms of completeness of TB diagnostics and 
higher FU rates. Explicit limitations are the incompleteness of data on ART and 
other HIV-related care determinants. Due to the small sample size of the 
interviews regarding counseling, patient support and treatment supervision the 
respective findings are of limited scientific value. 
However, this study has several strengths. By recruiting TB patients at all different 
health care sites which care for TB patients coverage of the area was highly 
comprehensive. Several different mycobacterial diagnostics were used to 
increase sensitivity; by shipping samples to the German reference laboratory we 
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obtained DST data despite the absence of respective infrastructure on the 
ground. Follow up strategy was maximized by active follow-up actions such as 
repeated phone calls. 
Although the catchment area of this study was broad, generalizability of the 
findings to the rest of the country or even region must be made cautiously. 40% 
of the Gabonese population is living in the urban capital where HIV prevalence is 
lower (3.9% vs. 5.8% [132]), concurrent parasitoses may be less prevalent, and 
where access to health care may differ. 
4.6 Conclusions 
Despite its ranking among the top ten high TB incidence countries, with a low 
population density, Gabon had so far failed to attract international attention or 
financial assistance to tackle this epidemic. The country relied almost exclusively 
on (insufficient) domestic funding for TB control activities. With a poorly resourced 
and underfunded TB control program, Gabon has fallen short of reaching most of 
the objectives of the Stop TB Strategy and is now faced with emergence and 
possible dissemination of MDR-TB cases, which represents a major public health 
threat both on the local and global scale. Concerted action is urgently needed to 
control the disease. 
These first prospective data on basic TB epidemiology and control in Gabon, 
Central Africa, document that in some parts of the world TB remains a major 
public health burden and a deadly infection despite the overall global progress in 
TB control over the past years. In this specific study area the ongoing TB burden 
is further determined by an unacceptably low rate of treatment success and a 
high default rate. The expansion of DOTS including decentralization of health 
services, promotion of health education and acknowledgement of cultural 
specifics is of paramount importance for effective TB control. MDR-TB is a 
threatening public health concern, in-country diagnostic capacity and access to 
second-line treatment regimens are urgently needed. Death of every third TB/HIV 
co-infected patient calls for urgent improvement of integrated TB and HIV care 
with special attention to INH resistance prevalence which may impair prevention 
of HIV-associated TB. National and international recognition of neglected 
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ongoing hot spots of the TB epidemic is a prerequisite in order to achieve global 
TB control and approach the vision of a world free of TB. 
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5 Summary 
BACKGROUND: Despite overall global progress in tuberculosis control over 
the past years, some regions are running behind. The central African country 
Gabon ranks number 10 in terms of TB incidence rate per 100,000 population 
according to the WHO, and the limited data available suggests alarmingly low 
treatment success rates. Disproportionately little is known about the reasons for 
adverse treatment outcome. The aim of the study and this thesis was to 
prospectively assess local TB determinants including treatment outcomes and 
to better understand the barriers towards successful treatment, as a 
prerequisite for effective TB control. 
METHODS: In a prospective observational cohort study TB patients were 
monitored during the course of their treatment in Lambaréné, Gabon. Clinical and 
microbiological data was collected at treatment initiation and after two and six 
months. TB treatment outcome was evaluated according to WHO definitions and 
risk factors for unfavorable treatment outcome and death were identified. 
Additionally, interviews were conducted with a subset of patients focusing on 
counseling, patient support and treatment supervision related to TB treatment. 
RESULTS: Between 2012 and 2014, 201 adult and pediatric TB patients were 
enrolled and followed up. The HIV co-infection rate was 42% in adults and 16% 
in children. Among culture confirmed TB patients the MDR-TB rate was 4/91 
(4.4%) and 4/13 (30.8%) in new and previously treated TB patients, respectively. 
Excluding MDR-TB patients, successful TB treatment was achieved in 55% of 
patients, 18% were lost to follow up and 9% died. Mortality rate was 29% in 
TB/HIV co-infected patients and 50% in patients with MDR-TB. Risk factors for 
adverse treatment outcome were far distance to treatment center and clinical 
diagnosis of TB, risk factors for death were HIV co-infection and clinical 
diagnosis, the only risk factor for default was long duration of cough. 
DISCUSSION: In Lambaréné, TB epidemiology is determined by a high rate of 
TB/HIV co-infection and a high rate of MDR-TB among re-treatment patients. 
Treatment success rates are low and a high percentage of patients is being lost 
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to follow up. Barriers towards successful treatment include geographical, financial 
and cultural aspects as well as lack in patient support and treatment supervision. 
For an effective TB control in Gabon, implementation of DOTS is of paramount 
importance. Furthermore, the access to diagnostic capacity for MDR-TB and 
second-line TB drugs as well as improvement of integrated TB/HIV care are 
urgently needed.  
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6 Summary in German language 
Hintergrund: Trotz der Fortschritte, welche in den letzten Jahren weltweit in 
der Bekämpfung der Tuberkulose erzielt wurden, liegen einige Regionen in der 
erfolgreichen Tuberkulosebekämpfung zurück. Das zentralafrikanische Gabun 
belegt gemäß WHO Platz 10 bezüglich Inzidenz pro 100.000 Einwohner und die 
wenigen verfügbaren Daten lassen auf eine beunruhigend geringe Erfolgsquote 
in der Tuberkulosetherapie schließen. Über die Ursachen ausbleibenden 
Therapieerfolgs ist verhältnismäßig wenig bekannt. Das Ziel der Studie und 
dieser Dissertation ist die prospektive Erfassung von lokalen Determinanten der 
Tuberkulose und das Aufzeigen von Hindernissen einer erfolgreichen 
Tuberkulosetherapie, als Voraussetzung für deren effektive Bekämpfung.  
Methoden: In einer prospektiven Beobachtungsstudie wurden Tuberkulose 
Patienten über den Zeitraum ihrer Behandlung in Lambaréné, Gabun 
nachverfolgt. Die klinische und mikrobiologische Datenerhebung erfolgte zu 
Therapiebeginn sowie nach zwei und sechs Monaten. Therapieerfolgsraten 
wurden nach WHO Definitionen ausgewertet und Risikofaktoren für 
ausbleibenden Therapieerfolg identifiziert. Zusätzlich erfolgte eine Befragung 
einer Subgruppe der Patienten zu Tuberkulose-spezifischer Beratung, 
persönlicher Betreuung und Therapiekontrolle.  
Ergebnisse: Zwischen 2012 und 2014 wurden 201 erwachsene und pädiatrische 
Tuberkulosepatienten eingeschlossen und nachverfolgt. Der Anteil an HIV-
Koinfektionen lag bei 42% der Erwachsenen und 16% der Kinder. Unter 
Patienten mit positiver Mykobakterien-Kultur betrug der Anteil an multiresistenter 
Tuberkulose (MDR-TB) jeweils 4/91 (4.4%) und 4/13 (30.8%) der Erst- und 
Rezidiv-Fälle. Die MDR-TB Patienten ausgenommen, wurden 55% der 
Tuberkulosepatienten erfolgreich behandelt, 18% brachen die Therapie ab und 
9% starben. Die Letalität der Patienten mit HIV-Koinfektion betrug 29% und jene 
der Patienten mit zu Therapiebeginn diagnostizierter MDR-TB 50%. 
Risikofaktoren für ausbleibenden Behandlungserfolg waren große Distanz zum 
Behandlungszentrum und klinisch diagnostizierte Tuberkulose, Risikofaktoren für 
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Tod waren HIV-Koinfektion und klinisch diagnostizierte Tuberkulose, der einzige 
Risikofaktor für Behandlungsabbruch war lange anhaltender Husten. 
Schlussfolgerungen: Die Epidemiologie der Tuberkulose in Lambaréné wird 
durch einen hohen Anteil an HIV-Koinfektionen und einen hohen Anteil an MDR-
TB unter Rezidiv-Patienten bestimmt. Die Erfolgsquote der Tuberkulosetherapie 
ist niedrig und Behandlungsabbrüche sind häufig. Hindernisse einer 
erfolgreichen Therapie umfassen geographische, finanzielle und kulturelle 
Aspekte so wie ein Defizit an persönlicher Betreuung und Therapiekontrolle. Die 
wichtigste Voraussetzung für die effektive Tuberkulosebekämpfung in Gabun ist 
die Umsetzung der DOTS-Strategie (Directly Observed Therapy, short course), 
welche in vielen anderen Ländern bereits erfolgreich eingesetzt wird. Weitere 
Anforderungen sind der Zugang zu Diagnostik von MDR-TB und Zweitrang-
Medikamenten sowie eine Verbesserung der Vernetzung zwischen Tuberkulose 
–und HIV Therapie.  
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